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ABSTRACT 
Modulation of Alpha-Subunit VISIT-DG Sequence Residues Ser-347, Gly-351 and Thr-
349 in the Catalytic Sites of Escherichia coli ATP Synthase 
by 
Laura E. Brudecki 
Binding of inorganic phosphate (Pi) in ATP synthase catalytic sites is a crucial step for 
the synthesis of adenosine-5‘-triphosphate (ATP).  ATP is the fundamental means of 
cellular energy in almost every organism, and in order to gain insight into the regulation 
of ATP catalysis, critical amino acid residues responsible for binding Pi must be 
identified.  Here, we investigate the role of highly conserved α-subunit VISIT-DG 
sequence residues αSer-347, αGly-351, and αThr-349 in Pi binding.  Mutations 
αS347A/Q, αG351Q, αT349A/D/R, βR182A, and αT349R/βR182A were generated via 
site directed mutagenesis.  Results from biochemical assays showed that αSer-347 is 
required for transition state stabilization and Pi binding whereas αGly-351 is only 
indirectly involved in Pi binding and most likely maintains structural integrity of the 
catalytic site.  Results from preliminary experiments on αThr-349 mutants suggest that 
the residue may be involved in Pi binding; however, further investigation is required to 
fully test this hypothesis. 
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CHAPTER 1 
INTRODUCTION 
Background 
ATP synthase is an enzyme found in nearly every organism ranging from bacteria 
to humans.  ATP synthase functions like a motor in order to generate the majority of 
cellular energy through the synthesis of adenosine-5‘-triphosphate (ATP) from 
adenosine-5‘-diphosphate (ADP) and inorganic phosphate (Pi).  
ATP synthase possibly could be one of the most ancient enzymes present on Earth 
today.  Homology between ATP synthase α and β proteins suggests that the gene 
duplication that gave rise to these two proteins occurred before the emergence of 
mitochondria (Cloud et al., 1969; Walker, 1982).   
In order for life to exist as we know it today, the formation of a barrier to the 
external environment, a cytoplasmic membrane, would have had to evolve.  There are 
many hypotheses as to how this happened, but as Mulkidjanian et al. (2009) state, the 
paradoxical chicken and egg scenario arises when trying to set forth an explanation.  A 
lipid bilayer could not exist without transport proteins or the cell would be excluded from 
the external environment altogether (Mulkidjanian et al., 2009). On the other hand, 
membrane proteins, due to their insoluble nature, would not have existed without the 
lipid bilayer encompassing them (Mulkidjanian et al., 2009).  So which came first?  
Mulkidjanian et al. (2009) and references therein propose that the first forms of life could 
recruit abiogenically formed amphiphilic molecules to form envelopes similar to modern 
viruses, but there are other hypotheses as to the beginnings of life.  Lane et al. (2010) 
propose a solution in the form of an abiotic lipid membrane.   
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Lane et al. (2010) discuss the origins of life at hydrothermal vents in the ocean.  
The type of vent discovered at the turn of the century, alkaline vents, have an inorganic 
membrane that creates a naturally occurring proton gradient (Lane et al., 2010).  In 
contrast to other hydrothermal vents such as black smokers, alkaline vents have a 
temperature around 70°C and a pH close to 10 (Lane et al., 2010; Wade et al., 2010).  
Lane et al. (2010) propose that these alkaline vents could have sustained early life and 
provided the necessary conditions for RNA replication.  Moreover, the naturally 
occurring inorganic membrane would have necessitated the emergence of a cytoplasmic 
membrane in order for life to escape the vent world (Lane et al., 2010).  A layer of 
primordial lipids, hydrothermally synthesized hydrophobic substances, could have been 
formed along the chambers created by the vents, just underneath the inorganic crust of 
the Earth (Lane et al., 2010).  Early life could have, at first, used this membrane before 
enzymatic lipid synthesis was possible (Lane et al., 2010).  Concomitantly, Mulkidjanian 
et al. (2008) take the stance that RNA and proteins preceded membranous cells, yet 
others (Segré et al., 2001) propose that life originated in a lipid world or even a protein-
less RNA-lipid world (Deamer, 2008; Poole et al., 1998; Szostak et al., 2001; Vlassov, 
2005).   
In order to move out of the inorganic membrane and synthesize lipids and other 
proteins, early life would need some way to generate energy.  Some theorize that the first 
organisms generated energy via fermentation pathways (De Duve, 2002; De Duve, 2005).  
Lane et al. (2010) make clear that fermentation, the pathway which Haldane (1929) and 
De Duve (2005) say must have been used by early life forms, does not seem to be a 
property our Last Universal Common Ancestor (LUCA) would possess.  Lane et al. 
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(2010) argue that most life today uses oxidative phosphorylation pathways, and those that 
do use fermentation pathways for ATP synthesis retain machinery needed for oxidative 
phosphorylation, such as proton-motive ATPases (Lane et al., 2010).  Fermentation does 
not require membrane bioenergetics; but active transport across the plasma membrane 
does and is necessary for homeostasis, uptake of nutrients, and flagellar motility (Lane et 
al., 2010).   
Above and beyond all of the previous points made by Lane et al. (2010) on why 
fermentation was not likely to be used by LUCA, he points out that bacteria and archaea 
have significantly different gene sequences for enzymes used in fermentation.  Noting 
that bacteria and archaea both have similar ATP synthase enzymes, it would hold that 
there was a common ancestor possessing an ATPase of some sort (Lane et al., 2010 and 
references therein).   
The common ancestor between archaea and bacteria would have been nothing like 
any life forms we see on Earth today.  Archaea and bacteria are different in so many 
ways: the glycerol moieties of the membrane phospholipids in all archaea and bacteria 
are of the opposite chiralities; with a few exceptions, the hydrophobic chains also differ, 
being based on fatty acids in bacteria and on isoprenoids in archaea; and in bacterial 
lipids the hydrophobic tails are usually linked to the glycerol moiety by ester bonds, 
whereas archaeal lipids contain ether bonds (Mulkidjanian et al., 2009).   
The presence of ATPases in almost every organism confirms an early 
development, but beyond that the use of the proton motive force itself is widespread.  
Peter Mitchell lists different organisms that take advantage of proticity and the ways in 
which they do so in his Nobel Lecture (Mitchell, 1978).  For example, there is the proton 
14 
 
motive bacteriorhodopsin system of Halobacterium halobium, the proton motive 
pyrophosphatase of photosynthetic bacteria, and protic heating in fat cell mitochondria of 
hibernating animals.  The rotatory flagellar motor of bacteria is driven by proticity.  
Moreover, there are proton motive ATPase and proton-coupled transporter systems in 
chloroplast envelope membranes, in the plasma membranes of moulds, yeasts, and higher 
plants, and also in the membranes of chromaffin granules and synaptosomes (Mitchell, 
1978). 
In bacteria and eukaryotic mitochondria and chloroplasts there are F-type 
ATPases which function in respiration to form energy (Mulkidjanian et al., 2009).  There 
are also V-type ATPases which are found in membranes of eukaryote vacuoles that serve 
as pumps (Mulkidjanian et al., 2009).  Mulkidjanian et al. (2007) propose that different 
types of ATP synthase may have arose from a RNA helicase and a membrane channel 
which came together and then integrated a translocated protein into the complex which 
then became a new subunit.  This is the rationale by which Mulkidjanian et al. (2007) 
explain homologous and non-homologous subunits between the two types of enzymes.  
Among the prokaryotic F-type and V-type ATPases there are both proton-
translocating and Na
+
-translocating forms (Mulkidjanian et al., 2009 and refernces 
therein).  The sodium ion binding sites within the F/V-ATPases are arranged nearly 
identical to one another (Mulkidjanian et al., 2008).  This infers that the common 
ancestor to these two types of ATPases could have been a sodium translocating enzyme 
(Mulkidjanian et al., 2008).  Differentiation of the two types could have stemmed from 
the organism in which the ATPase was incorporated.    
When discussing the origin of eukaryotic cells, many people recall the theory of 
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an endosymbiotic relationship between two organisms where one ends up being engulfed 
and incorporated into the other cell.  This is a good explanation of why mitochondria 
have a different genome.  Martin and Muller (1998) describe an alternate basis for which 
this event took place in their ‗Hydrogen Hypothesis.‘  According to their hypothesis, 
eukaryotes arose through a symbiotic association of an anaerobic, strictly hydrogen-
dependent, strictly autotrophic archaebacterium (the host) with a eubacterium (the 
symbiont) that was able to respire but generated molecular hydrogen as a waste product 
of anaerobic heterotrophic metabolism (Martin and Muller, 1998). 
As a result of this fusion, sodium ion transport as a mechanism for ATP synthesis 
may have become less imperative which may be why the use of Na
+
-translocating 
ATPases is not as prevalent in eukaryotes.  Perhaps some environmental selection 
pressure resulted in the development of strictly hydrogen transporters in which case there 
may have been a scenario in which a symbiotic relationship favored survival.  However, 
many organisms that are pathogenic to humans still use the sodium motive force for ATP 
synthesis (Häse et al., 2001).     
History of ATP Synthase Research 
In 1929 Karl Lohmann isolated adenosine-5‘-triphosphate (ATP) from muscle 
and liver extracts (Langen and Hucho, 2008).  In 1937 Kalckar uncovered a link between 
cellular respiration and ATP, and two years later Belitser and Tsibakova coined the term 
‗oxidative phosphorylation‘ (Feniouk, 2010).   
In oxidative phosphorylation, ATP is generated when oxygen is reduced to water 
with electrons donated from NADH and FADH2 (Nelson and Cox, 2005).  The high 
energy electrons are transferred exergonically by a series of membrane-bound electron 
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carriers, and the free energy which is generated is coupled to the transfer of protons 
across an impermeable membrane to an area of higher concentration (Nelson and Cox, 
2005).  This generates an electro-chemical potential.  Protons flow across the membrane 
down the concentration gradient through ATP synthase, a membrane protein that couples 
proton flow to phosphorylation of ADP (Nelson and Cox, 2005).   
Many scientists proposed chemical intermediates by which oxidative 
phosphorylation could occur, and it was not until 1961 that Peter Mitchell proposed the 
chemiosmotic hypothesis in which he suggested that there were no chemical 
intermediates, rather there were membrane proteins that maintained a proton gradient 
generated by respiration and ultimately used by ATP synthase as described above 
(Feniouk, 2010; Mitchell, 1961).  As with any scientific discovery, there are some 
discrepancies as to who actually made the discovery and who received credit for it.  
Prebble (1996) writes that Davies and Krebs published the essential elements of the 
chemiosmotic hypothesis nine years earlier but did not approach the concept with an 
actual hypothesis; hence, no actual experiments resulted from their statements (Prebble, 
1996).  Prebble (1996) closes his discussion stating that in this particular instance factors 
of advocacy, timeliness, potential for experimentation, and presentation were more 
important than primacy.   Mitchell formalized the hypothesis, which, after much scrutiny, 
became the chemiosmotic theory, and in 1978 he was awarded the Nobel Prize in 
chemistry for his contribution to bioenergetics (Feniouk, 2010; Mitchell, 1978; Nelson 
and Cox, 2005).   
In 1960 Efraim Racker and his lab purified a soluble ATPase and found that 
phosphorylation activity accompanied the enzyme (Penefsky et al., 1960; Pullman et al., 
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1960).  The enzyme responsible for oxidative phosphorylation was termed Factor 1 or F1.  
Due to its soluble nature, F1 may be gently stripped from the membrane during 
purification while remaining functionally intact.   
In 1977 Paul D. Boyer‘s group proposed the binding change mechanism by which 
F1FO ATP synthase functions (Boyer, 1979; Boyer, 2002).  This mechanism is described 
below in the Function section.  John E. Walker‘s lab is responsible for determining the 
genes that encode ATP synthase in the early 1980s, and in 1994 his group resolved the 
first x-ray crystallographic structure of F1 (Abrahams et al., 1994).   Walker, Boyer, and 
Skou received the 1997 Nobel Prize in Chemistry for their work on the mechanism for 
the synthesis of ATP and the discovery of an ion-transporting enzyme (Feniouk, 2010; 
http://nobelprize.org/nobel_prizes/chemistry/laureates/1997/).  Walker has continued to 
solve crystallographic structures of ATP synthase and has many structures under his 
name in the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data 
Bank online (Berman, et al., 2000).   
In 1997 Kinosita‘s lab performed single particle experiments that visually 
displayed the rotational catalysis of ATP synthase which will be discussed further in the 
Function section (Nakamoto et al., 2008; Noji et al., 1997).  In 2004 Itoh et al. showed 
that ATP synthase could be mechanically driven using the γ-subunit as a handle for 
magnetic bead attachment.  This work established the premise that understanding the 
manipulation of ATP synthase may be useful in developing nanomachines. 
In order for ATP synthase to serve as a base model for the development of 
nanomotors, we must first understand the mechanism of the enzyme.  Our lab has focused 
on understanding the role of key phosphate-binding amino acids within the α/β catalytic 
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sites of ATP synthase.  We have identified five residues required for phosphate binding: 
αSer-347, βArg-182, αArg-376, βLys-155, and βArg-246.  This thesis focuses on the 
work for αSer347, αGly351, and αThr349. 
αSer347, αGly351, and αThr349 are part of the VISIT-DG amino acid residue 
sequence which has been highly conserved throughout evolution (Li et al., 2009).  More 
importantly, this residue sequence lies in close proximity to the phosphate binding 
subdomain of the catalytic site (Li et al., 2009).  Therefore, we hypothesized that the 
residues of the VISIT-DG sequence may be playing some important catalytic and/or 
structural roles within the catalytic sites.  Selection of these three residues is discussed in 
more detail under the Modulation section.  
Structure 
The structure of ATP synthase is similar in all organisms with some residue 
sequences being highly conserved throughout evolution (Li et al., 2009).  The number of 
subunits varies across organisms, but the structure of each subunit is conserved.  
Eubacterial ATP synthase contains at least 22 subunits and eight different polypeptides 
(Nakamoto et al., 2008).  Thirteen of those subunits are membrane-bound (Nakamoto et 
al., 2008).   
  E. coli ATP synthase consists of eight subunits that are divided into two 
sectors.  The ~380kD, water-soluble F 1 sector contains subunits α3, β3, δ, ε, and γ, and is 
responsible for catalytic activity.  The membrane bound FO sector houses a, b2, and c10 
subunits and is the proton translocating sector (Boyer, 1997; Devenish et al., 2000; Hong 
and Pedersen, 2008; Karrasch and Walker, 1999; Li et al., 2009; Nakamoto et al., 2008; 
Senior, 1988; Senior et al., 2002).  Figure 1.1 shows the arrangement of subunits as 
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described above.  The membrane bound sector is designated ‗FO‘ for its sensitivity to 
oligomycin which is conferred by the oligomycin sensitivity conferring protein (OSCP) 
(Hong and Pedersen, 2008).  
As mentioned previously, F1 can be easily dissociated from FO in a reversible 
fashion.  However, dissociation renders F1 an ATPase alone and FO a passive proton pore 
(Nakamoto et al., 2008). When F1 is purified and gently removed from the water 
insoluble FO sector, a proton gradient cannot be established (Nelson and Cox, 2005). 
Protons leak from the FO pore just as fast as they are pumped by the electron transport 
chain (Nelson and Cox, 2005).  When F1 is returned to solution, it associates with FO, 
plugs the leaky pore and coupling of electron transfer and ATP synthesis is restored. 
(Feniouk, 2010; Kresge et al., 2006; Nelson and Cox, 2005). 
α3β3
γ
ε
c10
a
b2
δ
ADP + Pi ATP
Inner 
mitochondrial 
membrane
Mitochondrial 
matrix
FO
F1
 
FIGURE 1.1 Crystal structure of F1FO ATP synthase.  F1 is from Bovine, and FO and 
the stator are from E. coli.  The image has been altered from the RCSB PDB Molecule of 
the Month by Goodsell (2005). 
 
The α3β3 oligomer is arranged like segments of an orange, alternating between α 
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and β. The α and β subunits are highly conserved.  Seventy percent of the amino acids in 
bovine and E. coli ATP synthase are identical, and α and β proteins show persistent 
homology (Walker, 1982).  The γ subunit consists of a coiled coil that goes up into the 
α3β3 hexamer from its origin within the ring of c subunits as shown in Figure 1.1.  
Together, the γ, ε, and c subunits are the ‗rotor‘ unit of the complex which is responsible 
for rotational catalysis (Nakamoto et al., 2008).  The ‗stator‘ consists of the α3β3 hexamer 
and subunit a (Nakamoto et al., 2008). The pseudo hexamer is connected to a by the 
‗peripheral stalk‘ which is made up of two b subunits and one δ (Nakamoto et al., 2008).   
The number of c subunits is not known for every organism and the number is 
thought to vary among species.  However, there is some structural information for 
subunit c. The membrane-embedded hydrophobic subunit consists of a hairpin of two 
helical trans-membrane segments connected by a short hydrophilic loop facing the F1 
sector (Nakamoto et al., 2008).  There is an essential carboxylic acid near the middle of 
the carboxyl terminal trans-membrane helix which is typically a glutamate, but in some 
bacteria the carboxylic acid is an aspartate (Nakamoto et al., 2008).  The number of c 
subunits varies between 10 and 15 depending on the species (Nakamoto et al., 2008).   
Little is known about subunits a, b, or δ mostly because there is no high resolution 
crystal structure of the subunits or of the interactions between the two b subunits and δ 
(Nakamoto et al., 2008).  With regard to subunit a, there are likely five transmembrane 
segments which interact with the ring of c subunits to assist in the translocation of 
protons (Nakamoto et al., 2008). 
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Function 
ATP synthase uses the proton motive force, and in some cases the sodium motive 
force, to drive ATP synthesis during oxidative and photophosphorylation (Nakamoto et 
al., 2008). Oxidative phosphorylation occurs within the mitochondria of eukaryotes and 
the cytoplasmic membrane of bacteria (Bald et al., 1998; Boyer, 1997; Weber and Senior, 
1997) and archaea.  Photophosphorylation occurs within the thylakoid membrane of 
chloroplasts (Bald et al., 1998; Boyer, 1997; Weber and Senior, 1997) and cyanobacteria.  
In oxidative phosphorylation ATP is generated when oxygen is reduced to water 
with electrons donated from NADH and FADH2 (Nelson and Cox, 2005).  The high 
energy electrons are transferred exergonically by a series of membrane-bound electron 
carriers, and the free energy which is generated is coupled to the transfer of protons 
across an impermeable membrane to an area of higher concentration (Nelson and Cox, 
2005).  This generates an electro-chemical potential.  Protons flow across the membrane 
down the concentration gradient through ATP synthase, a membrane protein that couples 
proton flow to phosphorylation of ADP (Nelson and Cox, 2005).   
F1-ATPase has six nucleotide binding sites on the α/β hexamer; three are catalytic 
and three are non-catalytic (Bald et al., 1998).  Each of these sites is located on the 
interface between α and β.  ATP, ADP, and Pi bind at the βTP, βDP, and βE sites 
respectively.  Boyer (1979) proposed a ‗binding change mechanism‘ for the binding of 
ATP, ADP, and Pi in which each catalytic site changes to bind/release the products and 
substrates.  Clockwise rotation of asymmetric γ, as viewed looking up from the 
membrane, results in synthesis of ATP, and hydrolysis occurs during the anti-clockwise 
rotation.  This was shown in the single particle experiments of Itoh‘s group (Cabezon, et 
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al., 2003; Itoh et al., 2004; Noji et al., 1997).      
As protons flow through the c subunit, the γ subunit rotates creating 
conformational changes within the β subunit. For every 120° rotation, one ATP is 
synthesized: three ATP per 360° (Nakamoto et al., 2008).  In theory, if one proton is 
carried per c subunit, and three ATP are generated per 360° rotation, then the number of 
ions transported during one full rotation equals the number of c subunits (Nakamoto et 
al., 2008).  The number of ions transported divided by three provides the stoichiometry of 
ions required for ATP catalysis (Nakamoto et al., 2008).  
The 120° rotations can be broken down into two partial rotations of 80° and 40°.  
Before each 80° rotation there is a short dwell which is believed to be the rate limiting 
step when ATP binds.  The duration of the dwell is ATP-dependent and determines the 
rate of ATPase activity. In the reverse direction, ATP synthesis, the 40° rotation creates a 
high affinity for Pi, and the following 80° rotation reduces the affinity for ATP which 
allows the molecule to be released.  ATP release and Pi binding are the energy requiring 
steps during catalysis (Nakamoto et al., 2008).  Al-Shawi et al. (1990) postulated that the 
energy gained from binding Pi and the release of ATP during substrate-protein 
interactions is the driving force behind catalysis (Al-Shawi et al., 1990; Nakamoto et al., 
2008).  The importance of Pi binding is discussed in more detail below in the Modulation 
section.  
Human Health and Disease 
ATP plays a role in metabolic pathways within the cell and has implications in 
many diseases (Dadi et al., 2009; Hong and Pedersen, 2008).  For instance, mutation(s) in 
any one of the subunits of ATP synthase may cause Leigh syndrome, or a resistance to 
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darylquinoline, a new Tuberculosis drug (Andries et al., 2005; Cole and Alzari, 2005; 
Hong and Pedersen, 2008).  Mitochondrial DNA-associated Leigh syndrome is part of a 
continuum of progressive neurodegenerative disorders caused by abnormalities of 
mitochondrial energy generation (Thorburn and Rahman, 2006).  Neurodegenerative 
processes in Alzheimer‘s disease have been associated with the accumulation of α 
subunits in the intraneuronal cytosol (Schagger and Ohm, 1995). 
Common diseases such as obesity and high blood pressure have been correlated 
with ATP synthase as well (Hong and Pedersen, 2008).  Increases in blood pressure have 
been correlated with increased F6 circulating in the blood (Hong and Pedersen, 2008).  
When non-mitochondrial ATP synthase is inhibited, cytosolic lipid droplet accumulation 
decreased, implying ATP synthase as a potential anti-obesity drug target (Hong and 
Pedersen, 2008).    
Other diseases such as mitochondrial myopathies, Parkinson‘s, and cancer are 
correlated with ATP synthase (Hong and Pedersen, 2008).  A thorough review of 
mitochondrial pathology and the genetics of mitochondrial diseases can be found in 
Wallace (1999).  A few diseases mentioned in the review that are associated with genetic 
disorders are Leber's hereditary optic neuropathy (LHON), dystonia, Leigh's disease, 
Kearns-Sayre Syndrome (KSS), autosomal dominant-progressive external 
ophthalmoplegia (AD-PEO), mtDNA depletion syndrome, mitochondrial 
neurogastrointestinal encephalopathy syndrome (MNGIE), and Huntington's disease 
(Wallace, 1999).  
ATP synthase has been found on the extracellular surface of endothelial cells, a 
variety of cancer cells, and on neuronal cells (Chi and Pizzo, 2006; Xing et al., 2010). In 
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the case of tumor cells, the blocking of angiogenesis through reaction of inhibitors with 
non-mitochondrial ATP synthase has been shown: angiostatin has been shown to be 
antitumorigenic, and the β subunit is a target protein for innate antitumor cytotoxicity 
through the action of natural killer and interleukin 2-activated killer cells (Chi and Pizzo, 
2006; Gledhill et al., 2007; Hong and Pedersen, 2008).  In such cases ATP synthase 
could be a molecular target for various therapies.  There is no telling what the future may 
hold for cancer therapies.  Perhaps one day, lymphocytes could be grown, harvested, and 
directed towards the site of tumor growth, or various β subunit inhibitors could be 
injected at a tumor site in order to slow growth or reduce the size of a tumor without 
surgical invasion.  A thorough review of ATP synthase inhibitors can be found in Hong 
and Pedersen (2008).        
Understanding the role of ATP synthase in human disease conditions is 
imperative, but ATP synthase serves important roles in other organisms too.  For 
example, in insects juvenile hormone (JH) is responsible for reproductive development 
and metamorphosis.  As an insect matures the levels of JH drop off (Zalewska et al., 
2009).  By exposing larvae to JH, they are unable to develop further and they remain in 
the larval state (Zalewska et al., 2009).  This knowledge is used in agriculture: 
methoprene, a synthetic JH, is an insect growth regulator and is used to prevent the 
reproductive development of pest insects such as mosquitoes and insects in the orders 
Diptera, Lepidoptera, and Coleoptera (Csondes, 2004).   
Juvenile hormone, JH, needs to be transported to various cells in order to have an 
effect on development, and most of the time the hormone is bound by a protein known as 
juvenile hormone binding protein (JHBP) (Zalewska et al., 2009).  ATP synthase has 
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been identified as a JHBP-binding protein, and it was shown that ATP synthase is 
involved with transport of JHBP out of a cell (Zalewska et al., 2009).  The JHBP-JH 
complex will not bind to ATP synthase (Zalewska et al., 2009).   
The crystal structure of JHBP from Galleria mellonella shows an unusual fold 
consisting of a long α-helix wrapped in a highly curved antiparallel β-sheet 
(Kolodziejczyk et al., 2008).  JHBP structurally resembles the folding pattern found in 
tandem repeats in some mammalian lipid-binding proteins, with similar organization of 
one cavity and a disulfide bond between the long helix and the β-sheet (Kolodziejczyk et 
al., 2008).  Therefore, JHBP has an archetypal fold used by nature for hydrophobic ligand 
binding (Kolodziejczyk et al., 2008).  With structural and functional similarity between 
JHBP and mammalian lipid binding proteins, could there be an underlying medicinal 
application for understanding JHBP and its interactions with ATP synthase?  Perhaps by 
simply understanding the JHBP and ATP synthase protein-protein interactions we may 
come to understand more about bactericidal/permeability-increasing protein (BPI) and 
cholesteryl ester transfer protein (CETP), two mammalian lipid binding proteins 
(Zalewska et al., 2009).   
BPI is correlated with Chron‘s disease and ulcerative colitis which are both 
inflammatory bowel diseases (Petermann et al., 2009).  It was shown that upon addition 
of BPI, the β-subunit of the F1 portion of Escherichia coli ATP synthase was repressed 
threefold (Qi et al., 1995).  This shows that one mode of BPI‘s antimicrobial action is 
through the suppression of metabolic processes (Qi et al., 1995).    
Plasma HDL is a negative risk factor for atherosclerosis (Takahashi et al., 1993).  
Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester from HDL to other 
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lipoproteins (Takahashi et al., 1993).  Defects in CETP are associated with increased 
HDL cholesterol levels which are inversely correlated with risk of coronary artery disease 
(Takahashi et al., 1993).  Zhang et al. (2008) explored the effects of niacin on the surface 
expression of ATP synthase β chain, a newly described HDL/apolipoprotein A-I receptor 
for HDL endocytosis in HepG2 cells.  In their article Zhang et al. (2008) showed that α 
and β ATP synthase chains are specifically expressed on the cell surface of hepatocytes, 
endothelial cells, lymphocytes, and some tumor cell lines but not on the CHO cell line 
(Zhang et al., 2008).  Although the reason for expression on these specific cell types is 
not thoroughly understood, it may be involved in angiogenesis, hypertension, cell 
proliferation, and cytotoxicity in addition to HDL endocytosis (Zhang et al., 2008).   
Not only do the protein-protein interactions of ATP synthase and lipid binding 
proteins need to be understood on the cellular level, but these interactions must be 
understood from the genetic level in order for us to obtain a solid understanding of when 
and how these interactions are occurring, and what regulatory pathways are being 
involved during protein-protein interactions.  Defects in CETP have been associated with 
higher levels of HDL cholesterol.  Understanding the genetic basis for these defects may 
provide insight in targeting normal CETP or altering it to the defective form through gene 
therapy in order to benefit individuals with low levels of HDL cholesterol.  Using the 
arthropod system for research would provide an inexpensive means for understanding 
more about the role of ATP synthase in binding lipid binding proteins. 
Beyond using ATP synthase for a drug target or pharmaceutical development, we 
can use it as a prototype for a nanomotor.  ATP synthase exists in the body, interacting 
with any number of proteins and other molecules at any given time, so why not use this 
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enzyme as a base model to develop a tiny machine that can go inside our bodies to 
perform various types of work?   
Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical 
interventions on the molecular scale for curing disease or repairing damaged tissues 
(http://nihroadmap.nih.gov/nanomedicine/).  Unclogging arteries, fighting infections, or 
helping to monitor body systems are a few things nanomachines might be capable of.  
But once a nanomachine is inside the body, how big can it be?  How fast can it work? 
Can we alter its speed? How many can we have to perform efficiently without disrupting 
homeostasis? These questions must be addressed in order to build nanomachines that are 
compatible with living tissues and can safely operate inside the body (Ahmad and Senior, 
2005a; Whitesides, 2003; http://nihroadmap.nih.gov/nanomedicine/).   
Currently, ATP synthase is the smallest known biological nanomotor.  Therefore, 
understanding the mechanisms of how this enzyme works and using ATP synthase as a 
base model may help to develop nanomotors for nanomedicine usage.  This, of course, is 
the ultimate goal of our research.  For that reason, we focus on characterizing the 
catalytic sites of ATP synthase to find out which residues are responsible for binding 
inorganic phosphate (Pi), thus driving the synthesis of cellular ATP. 
Modulation 
Through mutagenic analysis, it is possible characterize individual residues, 
specifically within the α/β-catalytic sites.  Eight residues in close proximity to the 
catalytic site have been studied, and it was found that five residues (βArg-246, αArg-376, 
βLys-155, βArg-182, and αSer-347) are responsible for binding Pi, a  determining factor 
in the synthesis of ATP (Ahmad and Senior, 2004a, 2005b, 2006; Li et al., 2009); and 
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three residues (βAsn-243, βPhe-291, and αGly-351) were found to be important for 
overall function but not in Pi binding (Ahmad and Senior, 2004b; Brudecki et al., 2008; 
Li et al., 2009).   
The five residues responsible for Pi binding are within the phosphate-binding 
subdomain and are positioned in a triangular fashion.  The X-ray crystal structures of 
bovine ATP synthase show a sequence of residues that reside along the top of the 
triangular catalytic site: αVal-345, αIle-346, αSer-347, αIle-348, αThr349, αAsp350, and 
αGly-351.  These residues have been conserved throughout evolution and are known as 
the α subunit VISIT-DG sequence residues (Li et al., 2009).  VISIT-DG sequence 
residues may potentially be essential for Pi binding.  αSer-347 of the VISIT-DG sequence 
was the fifth residue recently found to be important for Pi binding (Li et al., 2009).  
However, αGly-351 has also been investigated for its role in Pi binding but was shown to 
play an indirect role (Li et al., 2009).   
For the work discussed herein, experiments were designed to test the hypothesis 
that other residues in this highly conserved region are important for Pi binding.  
Specifically, we asked if αThr-349 is directly involved in Pi binding: αThr-349 contains a 
hydroxyl side chain oriented towards the Pi binding cavity and may have a similar 
function to that of αSer-347.  Is the hydroxyl group on the side chain of αThr-349 
involved in charge communication with βArg-182 or important for transition state?  
In order to investigate the role of αThr-349, or other VISIT-DG residues, site-
directed mutagenesis can be employed.  Base pair mutations of various residues to 
alanine, aspartic acid, and arginine are helpful as they show how the native amino acid 
residue‘s side chain size and/or charge affect catalysis.  
29 
 
For example, alanine has a non-polar, neutral side chain which consists only of a 
methyl group (Fig. 1.2).  By replacing Thr with Ala, it is possible to test whether or not 
the hydroxyl group on the side chain of Thr is important for Pi binding.  As shown in 
Figure 1.2, aspartic acid has a negatively charged side chain.  By introducing Asp at 
position 349 in place of Thr we will be able to determine if Thr maintains some sort of 
structural integrity.  Arginine is a large, polar molecule with a positively charged side 
chain (Fig. 1.2).  By inserting a positive charge in place of threonine, will Pi binding be 
enhanced by the additional positive charge? Or will there be charge repulsion between 
the inserted arginine and the nearby βArg-182, a known Pi binding residue, which might 
result in loss of structural integrity and Pi binding elimination?  If this mutation is 
coupled with removing the positive charge of βR182, will αT349R compensate for the 
loss of βR182?  
There is a multitude of combinations that can be created in mutational studies.  
Once a residue of interest is chosen, mutant strains can be constructed using the logic 
above.  Then, each mutant strain must undergo a series of biochemical assays to 
determine what, if any, effect the mutation has and a role for the original amino acid 
residue is postulated.  
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FIGURE 1.2 Structure of amino acid residues. The structure, name, and one letter 
symbol for serine, threonine, glycine, alanine, aspartic acid, glutamine, and arginine are 
shown from left to right, top to bottom.   
 
Further characterization of function of mutant proteins involves testing how the 
ability to bind inhibitors is affected by the mutation.  ATP synthase activity can be 
inhibited by a multitude of compounds that can bind various locations on any one 
subunit.  The FO portion is named so for its oligomycin sensitivity-conferring protein 
(OSCP) (Hong and Pedersen, 2008).  The F1 subunit has binding sites for basic α-helical 
peptide inhibitors such as IF1 and melittin (Hong and Pedersen, 2008).  Hong and 
Pedersen‘s review (2008) discusses the action of inhibitors such as polyphenolic 
phytochemicals, polyketides, organotins, cations, substrate analogs, amino acid 
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modifiers, and other compounds on ATPase activity, as well as physical inhibition of 
activity by high hydrostatic pressure, low temperature, and UV irradiation.  Knowledge 
of inhibitor binding sites coupled with biochemical assays on mutant enzymes provides 
insight into how specific amino acids are contributing to the binding of various inhibitors.  
 Overall, this work will lead to a more thorough understanding of what residues 
are essential for binding Pi.  This knowledge will provide groundwork on which 
modulation of ATP synthase can be achieved and applied in the field of nanotechnology. 
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Abstract 
This paper describes the role of α-subunit VISIT-DG sequence residues αSer-347 
and αGly-351 in catalytic sites of Escherichia coli F1Fo ATP synthase. X-ray structures 
show the very highly conserved α-subunit VISIT-DG sequence in close proximity to the 
conserved phosphate-binding residues αArg-376, βArg-182, βLys-155, and βArg-246 in 
the phosphate-binding subdomain. Mutations αS347Q and αG351Q caused loss of 
oxidative phosphorylation and reduced ATPase activity of F1Fo in membranes by 100- 
and 150-fold, respectively, whereas αS347A mutation showed only a 13-fold loss of 
activity and also retained some oxidative phosphorylation activity. The ATPase of 
αS347Q mutant was not inhibited, and the αS347A mutant was slightly inhibited by 
MgADP-azide, MgADP-fluoroaluminate, or MgADP-fluoroscandium, in contrast to wild 
type and αG351Q mutant. Whereas 7-chloro-4-nitrobenzo-2-oxa-1, 3-diazole (NBD-Cl) 
inhibited wild type and αG351Q mutant ATPase essentially completely, ATPase in 
αS347A or αS347Q mutant was inhibited maximally by ~80–90%, although reaction still 
occurred at residue βTyr-297, proximal to the α-subunit VISIT-DG sequence, near the 
phosphate-binding pocket. Inhibition characteristics supported the conclusion that NBD-
Cl reacts inβE (empty) catalytic sites, as shown previously by x-ray structure analysis. 
Phosphate protected against NBD-Cl inhibition in wild type and αG351Q mutant but not 
in αS347Q or αS347A mutant. The results demonstrate that αSer-347 is an additional 
residue involved in phosphate-binding and transition state stabilization in ATP synthase 
catalytic sites. In contrast, αGly-351, although strongly conserved and clearly important 
for function, appears not to play a direct role.  
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Introduction 
F1Fo-ATP synthase is the enzyme responsible for ATP synthesis by oxidative or 
photophosphorylation in membranes of bacteria, mitochondria, and chloroplasts. It is the 
fundamental means of cell energy production in animals, plants, and almost all 
microorganisms. It works like a nanomotor and is structurally similar in all species. In its 
simplest form, as in Escherichia coli, it contains eight different subunits distributed in the 
water-soluble F1 sector (subunits α3β3γδε) and the membrane-associated Fo sector 
(subunits ab2c10). The total molecular size is ~530 kDa. In chloroplasts there are two 
isoforms of subunit b. In mitochondria, there are 7–9 additional subunits, depending on 
the source, but in toto they contribute only a small fraction of additional mass and may 
have regulatory roles (1–4).  
ATP hydrolysis and synthesis occur in the F1 sector. X-ray structures of bovine 
enzyme (5) established the presence of three catalytic sites at α/β subunit interfaces of the 
α3β3 hexamer. Proton transport occurs through the membrane-embedded Fo. The γ-
subunit contains three α-helices. Two of these helices form a coiled coil and are located 
in the central space of the α3β3 hexamer. Proton gradient-driven clockwise rotation of γ 
(as viewed from the membrane) leads to ATP synthesis and anticlockwise rotation of γ 
results from ATP hydrolysis. In recent terminology, the rotor consists of γεcn, and the 
stator consists of b2δ (6, 7). The function of the stator is to prevent co-rotation of catalytic 
sites with the rotor. Detailed reviews of ATP synthase structure and function may be 
found in Refs. 8–13.  
To better understand the reaction mechanism of ATP synthesis and hydrolysis and 
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their relationship to mechanical rotation in this biological nanomotor, we have focused 
our efforts on determining the role of conserved residues in and around catalytic site Pi-
binding subdomain. Knowledge of Pi-binding residues and residues surrounding the Pi-
binding subdomain is imperative for accomplishing (i) the molecular modulation of the 
catalytic site for the improved catalytic and motor function of this enzyme, (ii) an 
explanation of how ATP synthase binds ADP and Pi within its catalytic sites in the face 
of a relatively high ATP/ADP concentration ratio, and (iii) understanding the relationship 
between Pi binding and subunit rotation (14–16). Earlier attempts to measure Pi binding 
in purified E. coli F1 using [
32
P]Pi (15) or by competition with ATP or AMP-PNP
2
 in 
fluorescence assays of nucleotide binding (18, 19) failed to detect appreciable Pi binding 
at physiological Pi concentration. So, we turned to the assay devised by Perez et al. (20) 
in which the protection afforded by Pi against inhibition of ATPase activity induced by 
covalent reaction with 7-chloro-4-nitrobenzo-2-oxa-1, 3,-diazole (NBD-Cl) provides the 
measure of Pi binding. Earlier Orriss et al. (21) showed by x-ray crystallography that the 
covalent adduct formed by NBD-Cl is specifically in the βE catalytic site (Fig. 2.1A); 
thus protection afforded by Pi indicates that binding of Pi occurs at the βE catalytic site. 
By modifying the above assay for use with E. coli purified F1 or F1Fo membranes, we 
have previously investigated the relationship between Pi binding and catalysis for six 
residues, namely βArg-246, βAsn-243, αArg-376, βLys-155, βArg-182, and αPhe-291.3 
All of these residues are positioned in proximity to the phosphate analogs AlF3 or SO4
2- 
in 
x-ray structures of catalytic sites (22, 23). We found that four residues, namely βArg-246, 
αArg-376, βLys-155, and βArg-182, grouped in a triangular fashion are directly involved 
in Pi binding (Fig. 2.1B) (24–30).  
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FIGURE 2.1. X-ray structures of catalytic sites in mitochondrial ATP synthase showing 
spatial relationship of α-subunit VISIT-DG sequence αS347 and αG351. A, reacted NBD-O-
tyrosyl-297 in the βE site (21). B, the βDP site in the AlF4
-
 inhibited enzyme (23). E. coli residue 
numbering is shown. The triangle shows the residues βLys-155, βArg-182, βArg-246, αArg-376, 
and αSer-347 forming a triangular Pi-binding site. Rasmol software was used to generate these 
figures. 
It is interesting to note that Penefsky (31) detected [
32
P] Pi binding with a Kd (Pi) 
in the range of 0.1 mM in mitochondrial membranes using a pressure ultrafiltration 
method, and the results are in agreement with data obtained from the NBD-Cl protection 
assay (20). However, Penefsky could not detect Pi binding in E. coli F1Fo, and thus it is 
evident that Pi dissociates more rapidly from E. coli F1 than it does from mitochondrial 
F1. This unfortunately renders the potentially more convenient centrifuge column assay 
unsuitable with the E. coli enzyme.  
A mechanism of condensation of Pi with MgADP was proposed by Senior et al. 
(32). The x-ray crystallography structure of bovine ATP synthase by Menz et al. (23) 
shows the transition state analog MgADP-AlF4
-
 trapped in catalytic sites (Fig. 2.1B). It is 
clear from the geometry of this complex that the fluoroaluminate group occupies the 
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position of the ATP-γ-phosphate in the predicted transition state. Similarly, Pedersen and 
co-workers (33) reported the first transition state-like structure of F1 using enzyme 
obtained from rat liver and crystallized with the Pi analog vanadate (Vi). This work 
further demonstrated that ADP was not essential, suggesting that the MgVi-F1 complex 
inhibited the catalytic activity to the same extent as that observed for the MgADP-Vi-F1 
complex. Unfortunately, neither MgVi nor MgADP-Vi inhibits the E. coli enzyme (24). 
Thus we have relied on inhibition of ATPase activity by fluoroaluminate (or 
fluoroscandium) to assess the potential to stabilize a transition state complex (24–26, 28, 
30). Through mutagenesis and by employing the NBD-Cl protection assay as well as 
ATPase inhibition by transition state analogs, we can probe the direct or indirect role of 
residues in Pi binding. In this manuscript, we explore the possible role played by αSer-
347 and αGly-351 residues in the highly conserved α-subunit VISIT-DG sequence. Fig. 
2.1B shows the location of αSer-347 and αGly-351 residues. Notably, αSer-347 appears 
to occupy a strategic position in the Pi-binding subdomain. Fig. 2.2 shows the 
evolutionarily conserved α-subunit VISIT-DG sequence along with surrounding residues 
of α-subunit from a variety of species. The basic questions we asked were: what role does 
αSer-347 or αGly-351 play? Do the mutations αS347A, αS347Q, or αG351Q have any 
effect on Pi binding or transition state formation?  
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FIGURE 2.2. Amino acid sequence alignment of evolutionarily conserved α-subunit 
VISIT-DG sequence. α-Subunit sequence from different species is aligned. The highly 
conserved VISIT-DG sequence is highlighted in gray. The starting residue arginine 
shown here for E. coli is αR300. Conserved αSer-347 and αGly-351 are denoted by bold 
font. 
Materials and Methods 
Construction of Wild Type and Mutant Strains of E. coli—The wild type strain 
was pBWU13.4/DK8 (34). Mutagenesis was by the method of Vandeyar et al. (35). The 
template for oligonucleotide-directed mutagenesis was M13mp18 containing the HindIII-
XbaI fragment from pSN6. pSN6 is a plasmid containing the βY331W mutation from 
plasmid pSWM4 (36) introduced on a SacI-EagI fragment into pBWU13.4 (34), which 
expresses all the ATP synthase genes. pSWM67/AN888 strain was used for αS347A 
mutant (37). The mutagenic oligonucleotide for αS347Q was 
CCAACGTAATCCAGATTACCGATGG, where the underlined bases introduce the 
mutation and a new XcmI restriction site, and that for αG351Q was 
CCATTACCGATCAGCAAATCTTCCTGGAAACC, where the underlined bases 
introduce the mutation and a silent mutation removes BglII restriction site. DNA 
sequencing was performed to confirm the presence of mutations and absence of undesired 
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changes in sequence, and the mutations were transferred to pSN6 on a Csp451 (an 
isoschizomer of BstBI) and Pml1 fragment generating the new plasmids pZA13 
(αS347Q/βY331W) and pZA14 (αG351Q/βY331W). Each plasmid was transformed into 
strain DK8 (38) containing a deletion of ATP synthase genes for expression of the mutant 
enzymes. It may be noted that both mutant strains contained the βY331W mutation, 
which is valuable for measurement of nucleotide binding parameters (36) and does not 
affect function significantly on its own. Although the presence of βY331W mutation was 
not utilized in this work, the Trp mutation was included for possible future use.  
Preparation of E. coli Membranes, Measurement of Growth Yield in Limiting 
Glucose Medium, and Assay of ATPase Activity of Membranes—E. coli membranes were 
prepared as in Ref. 39. It should be noted that this procedure involves three washes of the 
initial membrane pellets. The first wash is performed in buffer containing 50 mM TES, 
pH 7.0, 15% glycerol, 40 mM 6-aminohexanoic acid, 5 mM p-aminobenzamidine. The 
following two washes are performed in buffer containing 5 mM TES, pH 7.0, 15% 
glycerol, 40 mM 6-aminohexanoic acid, 5 mM p-aminobenzamidine, 0.5 mM DTT, 0.5 
mM EDTA. Prior to the experiments, the membranes were washed twice more by 
resuspension and ultracentrifugation in 50 mM TrisSO4, pH 8.0, 2.5 mM MgSO4. Growth 
yield in limiting glucose was measured as in Ref. 40. ATPase activity was measured in 1 
ml of assay buffer containing 10 mM NaATP, 4 mM MgCl2, 50 mM TrisSO4, pH 8.5, at 
37 °C. The reactions were started by the addition of membranes and stopped by the 
addition of SDS to 3.3% final concentration. Pi released was assayed as in Ref. 41. For 
wild type membranes (20–30 μg of protein), reaction times were 5–10 min. For mutant 
membranes (40–60 μg of protein), reaction times were 30–50 min. All of the reactions 
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were shown to be linear with time and protein concentration. SDS gel electrophoresis on 
10% acrylamide gels was as in Ref. 42. Immunoblotting with rabbit polyclonal anti-F1-α 
and anti-F1-β antibodies was as in Ref. 43.  
Inhibition of ATPase Activity by NBD-Cl and Protection by MgADP or Pi—NBD-
Cl was prepared as a stock solution in dimethyl sulfoxide and protected from light. The 
membranes (0.2–0.5 mg/ml) were reacted with NBD-Cl for 60 min in the dark at room 
temperature in 50 mM TrisSO4, pH 8.0, 2.5 mM MgSO4, and then 50-μl aliquots were 
transferred to 1 ml of ATPase assay buffer to determine ATPase activity. Where 
protection from NBD-Cl inhibition by ADP or Pi was determined, the membranes were 
preincubated 60 min with protecting agent at room temperature before the addition of 
NBD-Cl. MgSO4 was present, equimolar with ADP or Pi. Control samples containing the 
ligand without added NBD-Cl were included. Neither Pi (up to 50 mM) nor MgADP (up 
to 10 mM) had any inhibitory effect alone.  
Reversal of NBD-Cl Inhibited ATPase Activity by DTT—For reversal of NBD-Cl 
inhibition by DTT, the membranes were first reacted with NBD-Cl (150 μM) for 1 h at 
room temperature, and then DTT (final = 4 mM) was added, and incubation continued for 
1 h at room temperature before ATPase assay. Control samples without NBD-Cl and/or 
DTT were incubated for the same times.  
Inhibition of ATPase Activity by Azide, Fluoroaluminate, or Fluoroscandium—
Azide inhibition was measured by preincubating membranes with varied concentrations 
of sodium azide for 30 min. Then 1 ml of ATPase assay buffer was added to measure the 
activity. For measurements of fluoroaluminate or fluoroscandium inhibition, the 
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membranes were incubated for 60 min at room temperature in 50 mM TrisSO4, 2.5 mM 
MgSO4, 1 mM NaADP, and 10 mM NaF at a protein concentration of 0.2–0.5 mg/ml in 
presence of AlCl3 or ScCl3 added at varied concentration (see ―Results‖). 50-μl aliquots 
were then added to 1 ml of ATPase assay buffer, and activity was measured as above. It 
was confirmed in control experiments that no inhibition was seen if MgSO4, NaADP, or 
NaF was omitted.  
Inhibition of ATPase Activity by Dicyclohexylcarbodiimide (DCCD)—Covalent 
modification of wild type and mutant membrane was performed as described by Weber et 
al. (44). ATPase activity was measured by adding 1 ml of ATPase assay buffer 
containing 10 mM NaATP, 4 mM MgCl2, 50 mM TrisSO4, pH 8.5, at 37 °C to the 100-μl 
aliquots of 16 h DCCD-modified ATP synthase.  
Results 
Growth Properties of αS347Q, αS347A, and αG351Q Mutants of E. coli ATP 
Synthase—Three new mutants, αS347Q, αS347A, and αG351Q, were generated. These 
two residues were chosen for mutagenesis because of their strong conservation in the α-
subunit VISIT-DG sequence and their close proximity to the Pi-binding pocket. The 
αS347A mutant was used to appreciate the role of Ser-OH side chain in Pi binding and 
transition state. αS347Q and αG351Q mutants were designed to understand the impact of 
larger side chain of Gln on αSer-347 and αGly-351.  
Table 2.1 shows that introduction of Gln as αS347Q and αG351Q resulted in the 
loss of oxidative phosphorylation. Both mutations prevented growth on succinate-
containing medium, and growth yields in limiting glucose medium were reduced close to 
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those of the ATP synthase null control. αS347A mutant, on the other hand, resulted in 
partial loss of oxidative phosphorylation. Specific ATPase activities of membrane 
preparations containing mutant enzymes were compared with wild type and null control, 
and the values are shown in Table 2.1. αS347Q and αG351Q reduced the ATPase activity 
by 100–150-fold, whereas ATPase activity was reduced only 13-fold by αS347A. 
Membranes prepared from the mutants contained the same amount of α and β subunits as 
wild type, as determined by SDS gel electrophoresis and immunoblotting (26) (data not 
shown); therefore, reduced ATPase is not due to impaired assembly of ATP synthase or 
loss of F1 during membrane preparation.  
TABLE 2.1 Effects of αSer-347 and αGly-351 mutation on cell growth and ATPase 
activity 
 
a
 Wild type, pBWU13.4/DK8; Null, pUC118/DK8, αS347Q/DK8, αG351Q/DK8, and 
αS347A/AN888. Both αS347Q and αG351Q mutants were expressed with the βY331W 
mutation also present, which does not significantly affect growth. The data are the means 
of four to six experiments each. 
b 
Growth on succinate plates after 3 days estimated by eye. ++++, heavy growth; +, 
partial growth; ±, very light growth; –, no growth. 
c
 ATPase activity was measured at 37°C and expressed as μmol of ATP 
hydrolyzed/min/mg of membrane protein. Each individual experimental point is itself the 
mean of duplicate assay tubes. The data are derived from two separate membrane 
preparations. The results from separate membrane preparations were in excellent 
agreement within ± 10%.  
  
 
Mutation
a
 
 
Growth on 
succinate
b
 
 
 
Growth yield in 
limiting glucose
 
 
ATPase  
activity
c
 
  % μmol/min/mg 
Wild type ++++ 100 28 
Null – 46 0 
βY331W ++++ 95 26 
αS347Q ± 55 0.20 
αS347A + 65 2.18 
αG351Q 
 
± 
 
54 
 
0.25 
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Inhibition of ATPase Activity of ATP Synthase in Membranes by NBD-Cl and 
Reversal by Dithiothreitol—We previously established that Pi binding by mutant or wild 
type ATP synthase can be assayed using either membrane preparations or purified F1, 
with equivalent results (24, 26). In this work we used membrane preparations that are 
more convenient. Fig. 2.3 shows NBD-Cl inhibition of wild type and mutant membranes 
in the presence of varied concentrations of NBD-Cl. In wild type potent inhibition 
occurred with no residual activity, and this is consistent with previous studies (24–28, 
30). αG351Q mutant was also completely inhibited, and αS347Q or αS347A mutant were 
inhibited by ~80–90% with ~20–10% residual activity. In previous studies (24–28, 30), 
we have noted several instances where mutant ATP synthases were incompletely 
inhibited by NBD-Cl. To be sure that maximal reaction with NBD-Cl had been reached, 
we incubated each membrane preparation with 150 μM NBD-Cl for 1 h as in Fig. 2.3, 
followed by an additional pulse of 200 μM NBD-Cl, continuing the incubation for an 
additional hour before assaying ATPase activity. Very little or no additional inhibition 
occurred (Fig. 2.4, left panel). This shows that the reaction of NBD-Cl was complete and 
that fully reacted αS347Q mutant membranes retained residual activity. Next, we checked 
whether inactivation by NBD-Cl could be reversed by the addition of the reducing agent 
DTT because reversibility by DTT was indicative of specificity of reaction in previous 
studies. Wild type and mutant enzymes were preincubated with 150 μM NBD-Cl as in 
Fig. 2.3, and then 4 mM DTT was added, and incubation continued for 1 h before 
ATPase assay. It was seen that DTT completely restored full activity in all cases (Fig. 
2.4, right panel). This indicates that NBD-Cl reacts specifically with residue βTyr-297 in 
the wild type as well as in both mutants (45, 46).  
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FIGURE 2.3. Inhibition of membrane-bound wild type and mutant ATP synthase by 
NBD-Cl. The membranes were preincubated for 60 min at room temperature with varied 
concentration of NBD-Cl, and then aliquots added to 1 ml of assay buffer and ATPase 
activity were determined. The details are given under ―Materials and Methods.‖ ●, wild 
type; ○, αS347A; �, αS347Q; Δ, αG351Q. Each data point represents an average of at 
least four experiments, using two independent membrane preparations of each mutant. 
The results agreed within ±10%. 
 
FIGURE 2.4. Results of extra pulse of NBD-Cl in mutants and reversal of NBD-Cl 
effects by DTT. Left panel, membrane ATP synthase was inhibited with 150 μM NBD-
Cl for 60 min under conditions as described in Fig. 2.3. Then a further pulse of 200 μM 
NBD-Cl was added, and incubation continued for 1 h before assay. Right panel, 
membrane ATP synthase (Mbr) was incubated with or without 150 μM NBD-Cl for 60 
min under conditions as described for Fig. 2.3. The degree of inhibition was assayed. In 
parallel samples, 4 mM DTT was then added, and incubation continued for further 60 
min before assay. Each set of bars represents wild type, αS347Q, αS347A, and αG351Q 
from left to right. The absolute residual ATPase activity values are as follows: wild type, 
28, 0.36, 0.22; αS347Q, 0.20, 0.03, 0.02; αS347A, 2.18, 0.44, 0.39; and αG351Q, 0.25, 
0.02, 0.01. 
45 
 
 
FIGURE 2.5. Protection against NBD-Cl reaction by MgADP. Wild type and mutant 
membrane were preincubated for 1 h at room temperature with varied concentrations of 
MgADP as shown, then 150 μM NBD-Cl was added, and incubation continued at room 
temperature in the dark for 1 h. The aliquots were then assayed for ATPase activity. ●, 
wild type; ○, αS347A; �, αS347Q; Δ, αG351Q. The results are the means of 
quadruplicate experiments which agreed within ±10%.  
MgPi protection against NBD-Cl reaction is presented in Fig. 2.6. It is evident that 
Pi protected well against NBD-Cl inhibition of ATPase activity in wild type and αG351Q 
mutant but did not protect at all against inactivation in αS347Q or αS347A mutants.  
 
FIGURE 2.6. Protection by Pi of ATPase activity in wild type (WT) and mutant 
membranes from inactivation by NBD-Cl. The membranes were preincubated with 
MgPi at 0, 2.5, 5, or 10 mM concentration as shown, for 60 min at room temperature. 
Then NBD-Cl (150 μM) was added, and aliquots were withdrawn for assay at time 
intervals as shown. ATPase activity remaining is plotted against time of incubation with 
NBD-Cl. ○, no Pi added;    , 2.5 mM Pi; �, 5 mM Pi; Δ, 10 mM Pi. Each data point 
represents the average of four different experiments using two independent membrane 
preparations of each mutant.  
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Inhibition of ATPase Activity by Fluoroaluminate, Fluoroscandium, and Azide—
We next examined the effects of transition state and ground state analogs. Fig. 2.7 (A and 
B) show inhibition of wild type and mutant enzymes by MgADP-fluoroaluminate and 
MgADP-fluoroscandium, respectively. Wild type and αG351Q were completely 
inhibited. αS347A showed only ~25% inhibition. In contrast, the mutant αS347Q was 
remarkably resistant to inhibition. Azide is also a potent inhibitor of ATPase in ATP 
synthase. Fig. 2.7C shows that although wild type is strongly inhibited by azide, the 
mutants showed varied resistance with ~70% inhibition in αG351Q and only ~20–25% 
inhibition in αS347Q and αS347A mutants.  
 
FIGURE 2.7. Inhibition of membrane ATPase activity from mutant and wild type 
ATP synthase enzymes by fluoroaluminate, fluoroscandium, and azide. The 
membranes were preincubated for 60 min at room temperature with 1 mM MgADP, 10 
mM NaF, and the indicated concentrations of AlCl3 (A) or ScCl3 (B). Then aliquots were 
added to 1 ml of assay buffer, and ATPase activity was determined. Sodium azide was 
added directly to the membranes and incubated for 30 min before assay (C), for details 
see ―Materials and Methods.‖ ●, wild type; ○, αS347A; �, αS347Q; Δ, αG351Q. All of 
the data points are the means of at least quadruplicate experiments. The variation was 
±10% between different experiments. 
Inhibition of ATPase Activity by DCCD—Fig. 2.8 shows the wild type and 
αS347Q, αS347A, and αG351Q mutant enzymes inactivated by DCCD. Although wild 
type is completely inhibited by 200 μM DCCD after16 h of incubation at room 
47 
 
temperature, mutants show varied degrees of inhibition. αG351Q is inhibited about 10%, 
αS347A is inhibited only ~30%, and αS347Q is not inhibited at all. In a similar series of 
experiments, carried out with the same range of DCCD concentrations and reaction 
conditions, but for only 2- or 5-h incubations, we found that wild type still became fully 
inhibited, αG351Q and αS347Q both showed zero inhibition, and αS347A was inhibited 
maximally by 6% (2 h) and 15% (5 h).  
 
FIGURE 2.8. Inhibition of membrane ATPase activity from mutant and wild type 
ATP synthase enzymes by DCCD. The membranes were preincubated for 16 h at room 
temperature with varied concentrations of DCCD indicated in the figure. Then 1 ml of 
ATPase assay buffer was added to determine the activity. ●, wild type; ○, αS347A; �, 
αS347Q; Δ, αG351Q. All of the data points are means of at least quadruplicate 
experiments. The variation was ±10% between different experiments.  
 
Discussion 
The goal of this study was to examine the functional role(s) of residue αSer-347 
and αGly-351 of E. coli ATP synthase. These residues are part of the strongly conserved 
α-subunit VISIT-DG sequence. The VISIT-DG sequence residues are located in close 
proximity to the α/β interface flanking the Pi-binding pocket (Fig. 2.1B). X-ray crystal 
structures of the AlF3-inhibited enzyme (22) as well as the AlF4
-
 inhibited enzyme (which 
also contained SO4
2-
 in a second catalytic site) (23) show that the side chain of residue 
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αSer-347 is very close to these bound Pi analogs (Fig. 2.1) and that αGly-351 is also 
close. Pi binding is a primary step in ATP synthesis by ATP synthase, thus exploring the 
molecular basis of Pi binding is an important way to examine and understand the 
functional role of residues in the catalytic site.  
Earlier studies established that mutagenesis combined with the use of the Pi 
protection assay against NBD-Cl inhibition, as well as the use of inhibitory analogs, 
enabled characterization of functional role(s) of residues suspected to be involved in Pi 
binding (24–30). From analysis of six such catalytic site residues, we determined that 
four residues, namely, αArg-376, βArg-182, βArg-246, and βLys-155, are critical for Pi 
binding and form a triangular subdomain within the catalytic site (24–30) (Fig. 2.1B). We 
also established that introduction of a negative or positive charge in this location resulted 
in drastic modulation of Pi binding (25, 26, 30), indicating that negative charge within the 
triangular subdomain was an important determinant of Pi binding. Here we used the same 
approaches to study residues αSer-347 and αGly-351.  
We introduced the mutations αS347Q, αS347A, and αG351Q, none of which 
affected assembly nor structural integrity of the membrane ATP synthase. Membranes 
showed similar content of F1-α and β subunits as compared with wild type. Both αS347Q 
or αG351Q mutations had severely inhibitory effects on oxidative phosphorylation as 
judged by growth on succinate or limiting glucose medium, and both strongly inhibited 
ATPase activity. On the other hand the αS347A mutation showed small residual 
oxidative phosphorylation and ATPase activity (Table 2.1). The results with the αS347Q 
and αS347A mutants showed that they abolished Pi binding (Fig. 2.6).  
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Although based on Table 2.1 data for αS347A mutant, it can be argued that there 
could be a small amount of Pi binding in cells but not significant enough to be 
measurable in the Pi binding assay of membranes (Fig. 2.6). Fluoroaluminate and 
fluoroscandium in combination with MgADP potently inhibit wild type E. coli ATP 
synthase (24–27, 30, 47, 48), and both are believed to mimic the chemical transition state. 
Transition state-like structures involving bound MgADP- AlF4
-
 complex have been seen 
in catalytic sites in ATP synthase by x-ray crystallography (23). It was evident that the 
αS347Q mutant strongly destabilized the transition state (Fig. 2.7, A and B), because no 
inhibition by MgADP-fluoroaluminate or MgADP-fluoroscandium was apparent. 
Clearly, therefore, residue αSer-347 is involved directly and to an important degree in 
catalysis and may be added as a fifth member of the group of Pi-binding residues that 
make up the triangular Pi-binding pocket. αS347A mutant did show some residual 
inhibition (~25%) with both MgADP-fluoroaluminate and MgADP-fluoroscandium, 
which is in agreement with the partial oxidative phosphorylation and ATPase activity 
found in this mutant. In contrast, the αG351Q mutation did not prevent Pi binding (Fig. 
2.6) and had lesser effects in destabilizing the transition state as judged by 
fluoroaluminate and fluoroscandium inhibition of ATPase (Fig. 2.7, A and B). Its effects 
on catalysis are therefore more indirect.  
All of the mutations affected the degree of inhibition by azide, with αS347Q 
reducing it substantially (by ~80%), αS347A reducing it substantially (~75%), and 
αG351Q reducing it by ~30% (Fig. 2.7C). A recent x-ray crystallography study (49) 
showed that azide inhibits ATP synthase by forming a tightly binding MgADP-azide 
complex in βDP catalytic sites, which resembles that formed by MgADP-beryllium 
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fluoride and may therefore be considered an analog of the MgATP ground state. In the 
MgADP-azide complex, azide occupies a position equivalent to that of the γ-phosphate of 
MgATP. Thus mutants also had effects on substrate binding by virtue of an effect at the 
γ-phosphate position.  
DCCD inhibits wild type E. coli F1 by reacting with residue βGlu-192 (50) and/or 
cAsp-61 (51), with the latter predominating at lower DCCD concentration and/or shorter 
incubation time. As expected, wild type ATP synthase was inhibited almost 100%. 
αS347Q mutant was not inhibited at all, αG351Q was inhibited to ~10%, and mutant 
αS347A is inhibited ~30% (Fig. 2.8). Notably, at shorter incubation times, αS347A 
showed even less inhibition (see ―Results‖). The data therefore indicate that in the 
αS347A mutant, ATPase activity on F1 is only partly coupled to proton translocation in 
Fo, which explains why αS347A mutant retains some growth on succinate and in limiting 
glucose (Table 2.1). It is interesting to note here that Pi binding and release events have 
been shown to be directly linked to rotation of the central stalk in single molecule 
experiments (52). Perturbation of the Pi-binding site might well be anticipated to perturb 
the integrity of the link between Pi binding and rotation and be manifested as uncoupling. 
The overall data on αS347A mutant strongly suggests that the Ser-OH group is needed 
for transition state stabilization and Pi binding.  
The availability of x-ray structures allows one to discuss in detail the roles of 
residues αSer-347 and αGly-351. αSer-347 is positioned close to bound AlF4
- 
in catalytic 
sites (Fig. 2.1B) (23). The Ser-OH lies 5.0 Å from the F1 and F3 atoms in AlF4
- 
and thus 
may contribute to transition state stabilization by direct interaction. 
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It may be remarked that a similar conclusion was reached regarding the Ser-OH 
of the highly conserved LSGGQ ABC signature sequence in P-glycoprotein (17).  
Considering how Pi binding is affected, αSer-347-OH lies 6.1 Å from atom O2 in SO4
2- 
(23) and 4.6 Å from F1 of AlF3 in the respective catalytic sites (22). Thus some direct 
interaction may be operative. However, more important than the above may be the fact 
that the Ser-OH lies 3.2 Å from the NH2 of βArg-246 (in the AlF4
- 
site) and 3.0 and 4.1 
Å, respectively from NH2 and NH1 of βArg-246 in the AlF3-occupied site. βArg-246 is 
strongly conserved and critical for Pi binding and transition state stabilization (24). 
Further, the carbonyl-O of αSer-347 lies 3.2 Å from NH2 of βArg-182, another Pi-binding 
residue. The likely H-bond interaction between αSer-347 and βArg-246 (and βArg-182) 
suggests these residues act together to support Pi binding and transition state stabilization. 
αGly-351 is located at a distance of 7.7 Å from AlF4
-
and 8.7 Å from SO4
2-
. A more 
indirect role in catalysis is therefore indicated, likely predominantly structural in nature.  
In summary, both αSer-347 and αGly-351 of the conserved VISIT-DG sequence 
in ATP synthase α-subunit are required for catalysis. αSer-347 plays the more important 
role and is required for Pi binding and transition state stabilization.  
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Abstract 
ATP synthase is responsible for the synthesis and hydrolysis of ATP, cellular 
energy.  Much is known about the structure and function of ATP synthase from various 
organisms and tissues, but more knowledge needs to be obtained in order to modulate the 
enzyme for use in nanotechnology.  In order to understand the catalytic mechanisms of 
ATP synthase, we must come to understand the role of residues within the Pi binding site.  
Pi binding is an essential part of ATP synthesis.  Five residues within the catalytic site 
have previously been shown to bind Pi.  Here we investigate the role of αThr-349 of the 
VISIT-DG sequence through mutagenic analysis.  αT349A/D/R, αT349R/βR182A, and 
βR182A mutants were generated.  Results from preliminary experiments suggest that 
αThr-349 may play a role in Pi binding, but further investigation is required.    
Introduction 
ATP synthase is an enzyme found in nearly every organism, ranging from 
bacteria to humans.  ATP synthase is also the smallest known molecular motor.  This 
enzyme is responsible for the majority of cell energy production through the synthesis of 
adenosine-5‘-triphosphate (ATP) from adenosine-5‘-diphosphate (ADP) and inorganic 
phosphate (Pi). The structure of this enzyme is similar in all organisms with some amino 
acid sequence residues being highly conserved throughout evolution (1-5).  E. coli ATP 
synthase consists of eight subunits that are divided into two sectors.  The water-soluble F 
1 sector contains subunits α3, β3, δ, ε, and γ, while the membrane bound FO sector houses 
a, b2, and c10 subunits (1-8).  F1-ATPase has six nucleotide binding sites on the α/β 
hexamer; three are catalytic and three are non-catalytic (9).  Each of these sites is located 
on the interface between α and β.  ATP, ADP, and Pi bind at the βTP, βDP, and βE sites, 
59 
 
respectively.   
Through mutagenic analysis, it is possible to characterize the function of 
individual amino acid residues, specifically within the α/β-catalytic sites.  Eight residues 
in close proximity to the catalytic site have been studied, and it was found that βArg-246, 
αArg-376, βLys-155, βArg-182, and αSer-347 are responsible for binding Pi, a  
determining factor in the synthesis of ATP (3, 10-12); and βAsn-243, βPhe-291, and 
αGly-351 were found to be important for overall function but not in Pi binding (3, 13, 
14)
1
.   
Alpha subunit VISIT-DG sequence residues are near to the phosphate-binding 
subdomain and may potentially be essential for Pi binding (3).  αSer-347 of the VISIT-
DG sequence was the fifth residue recently found to be important for Pi binding (3).  Is 
αThr-349 involved in Pi binding or transition state?  Is there a charge communication 
between the hydroxyl group of αThr-349 and its close neighbor βR182?  
We modulated the size and charge of αThr-349 by mutating it to arginine, alanine, 
and aspartic acid.  In order to test the hypotheses related to its involvement in Pi binding 
and structural support the following mutations were constructed: αT349A, αT349D, 
αT349R, R182A, and T349R/R182A.  We predict that αThr-349 has a similar 
function to that of αSer-347, that the mutations αT349A, αT349R, and αT349D will 
affect Pi binding and transition state, and that the mutation αT349R/βR182A will show a 
compensatory effect for the loss of βR182. 
Materials and Methods 
Construction of αThr-349 mutations in E. coli -- Site-directed mutagenesis was 
performed using a QuickChange Lightning Site-Directed Mutagenesis Kit from 
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Stratagene.  Plasmid DNA was isolated from pSN6, a βY331W mutant from a 
pBWU13.4/DK8 strain, which has been used in previous studies from our lab.  pSN6 is a 
plasmid containing the βY331W mutation from plasmid pSWM4 (15) introduced on a 
SacI-EagI fragment into pBWU13.4 (16), which expresses all the ATP synthase genes 
(3).This mutation was inserted into the wild-type strain for use in fluorescence studies 
and has not been shown to inhibit function of the enzyme (15).  Use of this strain enables 
new mutants to be used in fluorescence studies as well as our work of interest.   
The QuickChange Lightning Multi Site-Directed Mutagenesis Kit comes with a 
QuikChange Multi control template from the pBluescript II SK (-) which encodes for β-
galactosidase by the LacZ gene.  The use of the template along with the control primer 
mutates the template from having three early stop codons to a functional triple mutant for 
β-galactosidase (17, 18).  If the LacZ gene is interrupted, the cell will no longer be able to 
synthesize galactosidase, an enzyme responsible for the breakdown of lactose, and no 
color change will occur in the presence of IPTG, the gene‘s inducer, and X-Gal, the 
substrate for the enzyme (17, 18).  Hence, when the early stop codons are removed, the 
gene product will again be functional, and the presence of blue colonies will indicate that 
the mutagenesis was successful.  Mutagenic oligonucleotides are shown in Table 3.1.  
Reaction mixes were transformed into XL10-Gold Ultracompetent Cells and plated on 
LB ampicillin agar plates as per kit.  Colonies were picked from plates and grown in 10 
ml LB ampicillin broth for ~8 hr at 250 rpm.  Plasmid DNA was isolated using a 
Promega Wizard Plus SV MiniPrep Kit.  Supernatant from the first pellet was saved for 
sample recovery.  Mutant DNA was transformed into strain DK8 and sent for sequencing 
to test for any undesired changes and that the desired mutation was correct. Strain DK8 
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contains a deletion of ATP synthase genes for expression of the mutant enzymes (3).   
TABLE 3.1 Mutagenic oligonucleotides for constructing αT349 and βR182 mutants 
Strain Mutation Mutagenic Oligonucleotide 
New 
Restriction 
Site 
pLEB5 
αT349R/βY331W GTTCCGACCAACGTAATCTCCATT
CGCGATGGTCAGATCT 
NruI 
pLEB10 
αT349D/βY331W GTTCCGACCAACGTAATCTCAATT
GACGATGGTCAGATCTTCCTGG 
MfeI 
pLEB13 
αT349A/βY331W GTTCCGACCAACGTAATCTATAG
CCGATGGTCAGATCTTCCTG 
SfcI 
pLEB14 
βR182A/βY331W GTTTGCGGGCGTAGGTGAAGCTA
CTCGTGAGG 
AluI 
pLEB15 
αT349R/βR182A/
βY331W 
The oligonucleotide for pLEB14 was 
used on the pLEB5 plasmid 
NruI and 
AluI 
All mutants were expressed with the βY331W mutation also present.  The underlined 
nucleotide bases introduce the new mutation, and bold letters signify a silent mutation.  
Mutations and silent mutations inserted new restriction sites; however, plasmids were 
sent directly for sequencing and were not screened using restriction digestion.  
 
Newly developed mutants, αT349A, αT349D, αT349R, βR182A, and 
αT349R/βR182A, were assayed for growth and used in biochemical.   
Growth in Limiting Glucose and on Succinate Medium--Modulation of these 
residues was undertaken using growth on limiting glucose and succinate media and 
through biochemical assays.  Mutants were grown in limiting glucose media as in (19).  
Growth was measured by reading the OD595 every hour until the growth reached late log 
phase.  Succinate minimal media plates were also streaked and grown overnight as in (3).  
Plates were left out at room temperature for further growth.  Growth on succinate plates 
were given a rating of no growth (-), partial growth (++), and heavy growth (+++) for the 
next three days.  Growth on succinate and limiting glucose were compared.  Once growth 
assays are completed satisfactorily, bacterial membrane-bound F1FO preparations will be 
made for use in biochemical assays.   
Preparation of E. coli membrane bound ATP synthase—Membrane-bound F1FO 
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ATP synthase was prepared as in (20).  Membrane pellets were washed three times in 
buffer.  The first wash is performed in buffer containing 50 mM TES, pH 7.0, 15% 
glycerol, 40 mM 6-aminohexanoic acid, 5 mM p-aminobenzamidine. The following two 
washes are performed in buffer containing 5 mM TES, pH 7.0, 15% glycerol, 40 mM 6-
aminohexanoic acid, 5 mM p-aminobenzamidine, 0.5 mM dithiothreitol (DTT), and 0.5 
mM EDTA.  Pellets were finally resuspended in 50mM Tris-Sulfate, pH 8.0, and 2.5mM 
MgSO4, and stored in -20°C.  
Concentration of total protein was found using the method of Bradford (21).  
ATPase activity was measured in 1 ml of assay buffer containing 10 mM NaATP, 4 mM 
MgCl2, 50 mM TrisSO4, pH 8.5, at 37 °C. Addition on membranes began the reaction 
and the addition of SDS
2
 to 3.3% final concentration stopped the reaction. Pi released was 
assayed as in (22). For wild type membranes (20–30 μg of protein), reaction times were 
5–10 min. For mutant membranes (20–100 μg of protein), reaction times were 15–90 
min. All of the reactions were shown to be linear with time and protein concentration.  
NBD-Cl (7-chloro-4-nitrobenzo-2-oxa-1, 3-diazole) inhibition, extra pulse of 
NBD-Cl, reversibility of NBD-Cl inhibition by DTT, and protection from NBD-Cl 
inhibition by MgADP and MgPi assays were used to show if the mutant catalytic sites are 
still able to bind inhibitors and substrates and to what degree they favor binding.   
Inhibition of ATP Synthase activity by NBD-Cl, Extra Pulse of NBD-Cl, and 
Reversal of NBD-Cl Inhibition by DTT —NBD-Cl was prepared as a stock solution in 
dimethyl sulfoxide and protected from light. The membranes (0.2–1 mg/ml) were reacted 
with NBD-Cl for 60 min in the dark at room temperature in 50 mM TrisSO4, pH 8.0, 2.5 
mM MgSO4, and then 50-μl aliquots were transferred to 1 ml of ATPase assay buffer to 
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determine ATPase activity.  For extra pulse of NBD-CL, the membranes were first 
reacted with NBD-Cl (150 μM) for 1 h at room temperature, and then reacted with an 
extra pulse of NBD-Cl (150 μM) for an additional hour at room temperature before 
ATPase assay.  Control samples without NBD-Cl were incubated for the same times.  For 
reversal of NBD-Cl inhibition by DTT, the membranes were first reacted with NBD-Cl 
(150 μm) for 1 h at room temperature, and then DTT (final = 4 mm) was added, and 
incubation continued for 1 h at room temperature before ATPase assay. Control samples 
without NBD-Cl and/or DTT were incubated for the same times.  
Protection of ATP Synthase Activity from Inhibition  by NBD-Cl with MgADP and 
MgPi--Membranes were preincubated 60 min with protecting agent at room temperature 
before the addition of NBD-Cl. MgSO4 was present, equimolar with ADP or Pi. ATPase 
activity was assayed after 0 min to 1 h incubation with NBD-Cl in 5 min increments.  
Control samples containing the ligand without added NBD-Cl were included. Neither Pi 
(up to 50 mM) nor MgADP (up to 10 mM) had any inhibitory effect alone. 
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Results 
TABLE 3.2 Effects of αThr-349 and βArg-182 mutation on cell growth and ATPase 
activity  
 
Mutation
a
 
 
 
 
Growth on 
succinate
b
 
 
 
Growth yield in 
limiting glucose
 
 
ATPase 
 activity
c
 
 
  % μmol/min/mg 
Wild type ++++ 100 7 
Null – 37 N/A 
βY331W ++++ 94 N/A 
αT349R ++ 49 .07 
αT349D ++ 61 .4 
αT349A ++ 55 2 
βR182A ++ 47 .01 
αT349R/βR182A
 
+ 
 
48 
 
0.2 
 
aWild type, pBWU13.4/DK8; Null, pUC118/DK8, αT349R/DK8, αT349D/DK8, and 
αT349A/DK8.  
b
Growth on succinate plates after 3 days estimated visibly. ++++, heavy growth; ++, 
partial growth; –, no growth.   
cATPase activity was measured at 37°C and expressed as μmol of ATP 
hydrolyzed/min/mg of total protein.  Data represent the mean from four to six assays.  
Data were obtained from one growth experiment and one membrane preparation and 
should not be considered conclusive.  N/A= not assayed.    
Growth properties of mutant enzymes--Once mutagenesis was completed, growth 
was assayed in limiting glucose and on succinate plates.  Growth on Succinate, a non-
fermentable carbon source, reveals the level of oxidative phosphorylation that may be 
achieved for the mutant strains.  All mutants had a loss of oxidative phosphorylation.  
With the exception of αT349D, all mutant growth in limiting glucose was reduced to that 
of the null (pUC118).  As shown in Table 3.2, growth on succinate and limiting glucose 
seemed to correlate, but as mentioned in the table legend, these assays need to be 
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duplicated in order to be conclusive.  ATPase activity levels were low for all strains.  
Wild-type ATPase activity is generally ~28 μmol/min/mg, as in (3), but is only 7 
μmol/min/mg from this particular membrane preparation.  Low ATPase activity can 
result from poorly purified membrane, exposure to ambient temperatures, loss of F1 
during membrane prepartion,  or chemical contaminants (3).  Table 3.2 shows that in 
comparison to wild-type, ATPase activity of αT349R was reduced 100-fold, αT349D 18-
fold, αT349A 4-fold, βR182A 700-fold, and αT349R/βR182A 40-fold.   
Inhibition of ATP Synthase activity by NBD-Cl, Extra Pulse of NBD-Cl, and 
Reversal of NBD-Cl Inhibition by DTT-- NBD-Cl inhibition was assayed for wild-type 
and all mutant membrane-bound F1FO ATP synthase.  Purified F1 was not used in any of 
the following biochemical assays, as it has been shown that purified F1 and membrane-
bound F1FO behave similarly (3).  In Figure 3.1, wild-type is shown to be completely 
inhibitied by NBD-Cl.  X-ray crystallographic structures have shown that NBD-Cl binds 
to βY311 in bovine ATP synthase (βY297 in E. coli) by a covalent bond which results in 
loss of function (3, 23).  αT349A behaved as wild-type and was potently inhibited with 
no residual activity.  αT349R and αT349D were inhibited ~80-90%, maintaining ~20-
10% residual activity.  βR182A and αT349R/βR182A were inhibited only by ~50%.   
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Figure 3.1. Inhibition of ATPase activity by NBD-Cl. The membranes were 
preincubated for 60 min at room temperature with varied concentrations of NBD-Cl, and 
then aliquots were added to 1 ml of assay buffer and ATPase activity was determined. 
The details are given under ―Materials and Methods.‖ Black, wild type; red, αT349R; 
orange, αT349D; yellow, αT349A; green, βR182A; blue, αT349R/βR182A. Each data 
point represents an average of at least two experiments. 
In previous studies, mutant enzymes were not always completely inhibited by 
NBD-Cl.  For this reason, we performed the NBD-Cl inhibition assay and after the initial 
one hour incubation with inhibitor, we applied an extra-pulse of 150 μM NBD-Cl 
followed by an additional hour of incubation (Figure 3.2).  It was shown that little to no 
further inhibition is achieved, which confirms that some mutants do retain residual 
activity when reacted with NDB-Cl.   
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Figure 3.2. Inhibition by an Extra Pulse of NBD-Cl.  Membrane ATP synthase was 
inhibited with 150 μM NBD-Cl for 60 min under conditions as described in Fig. 3.1. 
Then a further pulse of 150 μM NBD-Cl was added, and incubation continued for 1 h 
before assay.  Each set of bars represents wild type, αT349R, αT349D, αT349A, 
βR182A, and αT349R/βR182A from left to right.   
 
The NBD-O-Tyrosyl-297 covalent bond can be reversed through reaction with 
dithiothreitol (DTT) (23-25).  Thus, reversal of NBD-Cl inhibition by DTT confirms that 
the NBD-Cl reacted in the βE catalytic site with Tyr-297 (3, 23-25).  Figure 3.3 shows 
that reversal of inhibition was obtained in wild-type and mutant enzymes, confirming the 
reaction of NBD-Cl and βTry297. The absolute residual ATPase activity values are as 
follows: wild type, 6.47, 4.40, 6.54; αT349R, 0.07, 0.06, 0.07; αT349D, 0.55, 0.42, 0.55; 
αT349A, 2.40, 1.70, 2.27; βR182A, 0.01, 0.01, .001; and αT349R/βR182A, 0.02, 0.01, 
0.02.   
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DTT Reversibility
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Figure 3.3. Reversal of NBD-Cl effects by DTT. Membrane ATP synthase was 
incubated with or without 150 μM NBD-Cl for 60 min under conditions as described for 
Fig. 3.1. In parallel samples, 4 mM DTT was then added, and incubation continued for 
further 60 min before assay. Each set of bars represents wild type, αT349R, αT349D, 
αT349A, βR182A, and αT349R/βR182A from left to right.  
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FIGURE 3.4. Protection by MgADP against NBD-Cl inhibition. Wild type and mutant 
membranes were preincubated for 1 h at room temperature with varied concentrations of 
MgADP as shown, then 150 μM NBD-Cl was added, and incubation continued at room 
temperature in the dark for 1 h. The aliquots were then assayed for ATPase activity. 
Black, wild type; red, αT349R; orange, αT349D; yellow, αT349A; green, βR182A; blue, 
αT349R/βR182A. The results are the means of at least two experiments. 
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Protection of ATP Synthase Activity from Inhibition  by NBD-Cl with MgADP and 
MgPi--MgADP (Fig. 3.4) and MgPi (Fig. 3.5A, B, C, D, E, and F) were used to protect 
ATP synthase from NBD-Cl inhibition.  In Figure 3.4, βR182A and αT349R/βR182A 
show considerable protection, while wild-type and other mutants only show partial 
protection.   
There appears to be some Pi protection in the αT349A mutant (Fig. 3.5D) but not 
in the αT349R (Fig. 3.5B) and αT349D mutant (Fig. 3.5C).  αT349A was inhibited to 
completion in the NBD-Cl assays (Fig. 3.1), but here retains some residual activity when 
treated with MgPi (Fig. 3.5D).  Mutants αT349R and αT349D are inhibited as in Figure 
3.1 which shows that MgPi treatment had no bearing on the degree of inhibition(Fig. 3.5B 
and C).  Data are inconclusive with the βR182A (Fig. 3.5E) and αT349R/βR182A 
mutants (Fig. 3.5F).  Aside from WT and pLEB13, which were both repeated once, the Pi 
assays were only completed one time.  Therefore, Figure 3.5A, B, C, D, E, and F are 
results from preliminary experiments and the assays need to be repeated to confirm 
resolution of the data points.  
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FIGURE 3.5. Protection by MgPi against NBD-Cl inhibition. The membranes were 
preincubated with MgPi at 0, 2.5, 5, or 10 mM concentration as shown, for 60 min at 
room temperature. Then NBD-Cl (150 μM) was added, and aliquots were withdrawn for 
assay at time intervals as shown. ATPase activity remaining is plotted against time of 
incubation with NBD-Cl. black, no Pi added; red, 2.5 mM Pi; green, 5 mM Pi; blue, 10 
mM Pi. A, WT; B, αT349R; C, αT349D; D, αT349A; E, βR182A; F, αT349R/βR182A. 
Each data point represents one experiment. 
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Sodium azide, fluoroaluminate, fluoroscandium, and DCCD assays have not yet 
been performed.  In order to assess effects of mutations on transition state and coupling, 
these assays must be completed.   
Discussion 
Due to the highly conserved nature of ATP synthase α subunit VISIT residues and 
their close proximity to the Pi binding subdomain, VISIT sequence residues are of 
interest when characterizing phosphate binding residues in ATP synthase.  Previously it 
was shown that αSer-347 is important for Pi binding, and that the –OH side chain of 
serine is required for transition state stabilization (3).  The current work investigated the 
role of αThr-349 through the introduction of mutations αT349R, αT349D, αT349A, 
βR182A, and αT349R/βR182A.   
Mutant enzymes showed a loss of oxidative phosphorylation as well as a decrease 
in ATPase activity compared to that of wild-type (Table 3.2).  Certainty as to whether 
loss of function was due to mutation or structural integrity of the mutant enzymes is not 
clear.   
NBD-Cl was able to bind the βE site of each mutant generated as shown by the 
DTT reversibility assay (Fig. 3.3).  However, maximal NBD-Cl inhibition was not 
reached in all mutants:  βR182A and αT349R/βR182A retained ~50% residual activity; 
αT349A behaved as wild-type and was potently inhibited with no residual activity; 
αT349R and αT349D were inhibited ~80-90%, and maintained ~20-10% residual 
activity.  
Through the MgPi assays, we found that mutants αT349R and αT349D appear not 
to be protected from NBD-Cl inhibition due to loss of Pi binding, but αT349A appears to 
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have afforded some protection against NBD-Cl inhibition (Fig. 3.5 B, C, and D).  These 
results imply that the size and charge may be important for αT349 to bind Pi and that the 
–OH side chain may not play a role in direct Pi binding.  However, due to the preliminary 
nature of these results and the absence of transition state assays, we are unable to make 
any definite conclusions as to the role of αT349 in direct or indirect Pi binding at this 
time.  Mutations do seem to have some effect on function, but further investigation is 
required in order to identify the specific effects.   
Additional work needed to characterize the role of αThr-349 and its relationship 
with βR182 entails completing fluoroaluminate, fluoroscandium, and sodium azide 
assays.  Inhibition by DCCD should be analyzed.  In order to characterize the effect 
mutations have on folding, fluorescence studies could be performed with the newly 
generated mutants as they all contain the βY331W mutation.     
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CHAPTER 4 
CONCLUSIONS AND DIRECTIONS FOR FUTURE WORK 
Conclusions 
The ATP synthase α subunit VISIT-DG sequence residues seem to play an 
important role in structure and/or function of the enzyme because of their highly 
conserved nature and close proximity to the catalytic site.  αSer-347 of the VISIT-DG 
sequence has been shown to be required for Pi binding.  This provides rationale for 
investigating the role of the other VISIT-DG residues.   
The goal of this work was to understand which amino acid residues in and around 
the catalytic site are responsible for binding Pi.  We established that αSer-347 of the 
VISIT-DG residue sequence is required for Pi binding, and that αGly-351 is not required 
for binding Pi but is important for function of the enzyme.  Preliminary experiments for 
αThr-349 provide adequate reason to presume that this residue may also be required for 
Pi binding, but further investigation is required.   
In order to use ATP synthase as a base model for nanomotor development, we 
must understand how the catalytic site can be modulated for improved catalytic function.  
Although solid conclusions may not be drawn from preliminary experiments on αThr-349 
and its interactions with βArg-182, data suggest that loss of βArg-182 cannot be 
compensated for by insertion of arginine in place of αThr-349.  If the mutation was able 
to compensate for the loss of the known Pi binding βArg-182 residue, we would expect 
behavior in biochemical assays to be similar to wild type.  However, this is not observed.     
Prior to this work, we were aware of four amino acid residues, βArg-246, αArg-
376, βLys-155, and βArg-182, required for phosphate binding in the catalytic sites of E. 
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coli ATP synthase (Ahmad and Senior, 2004a, 2005b, 2006).  Today we can add αSer-
347 to our list of known phosphate binding residues (Li et al., 2009).   
Future Directions 
Phosphate analog and DCCD assays have not yet been performed on the αThr-
349 and βArg-182 mutants, and most assays performed and discussed in Chapter 3 need 
more replicates.  Fluorescence studies should be performed on the newly developed 
mutants in order to access the effect of mutations on protein folding.  Mutations for the 
remaining residues in the VISIT-DG sequence have been constructed and need to be 
analyzed as well.  These mutations are shown in Appendix E.    
All of the assays used for this work measure ATPase activity, and the assay for Pi 
binding is an indirect measurement.  A direct Pi binding assay would enhance these 
studies greatly because synthesis and hydrolysis reactions are not one in the same.  
Weber and Senior (2000) state that little is known about ATP synthesis.  The mechanism 
by which ADP and Pi bind is not understood (Weber and Senior, 2000).  ATP synthesized 
can be measured through the use of the bioluminescent luciferin/luciferase assay (Dupaix 
et al., 1989; Itoh et al., 2004).  Investigation of the effect of VISIT-DG mutations on 
ATP synthesis through the use of the luciferin/luciferase system may help to understand 
the structural and functional differences between ATP synthesis and ATPase activity.   
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APPENDICES 
Appendix A 
Buffers and Reagents 
50 mM Tris-SO4 buffer 
 To 90 ml H2O add 
 0.61 g Tris 
 Adjust pH to 8.0 with 6M H2SO4 
 Bring to a final volume of 100 ml with H2O 
 
ATPase cocktail 
 In 150 ml H2O add 
 10 ml 1 M Tris 
 0.8 ml 1M MgCl2 
 5 ml 0.4 NaATP (Adenosine 5 -triphosphate disodium salt) 
o Add NaATP slowly to H2O while maintaining pH 5-9 with 6M NaOH. 
 Adjust pH to 8.5 with 6M H2SO4 
 Bring to a final volume of 200 ml with H2O 
 Freeze in plastic bottles at -20°C 
 
10 % SDS 
 100 g sodium dodecyl sulfate 
 Bring to a final volume of 1000 ml with H2O 
 
Taussky and Shorr (T&S) reagent 
 Sol A: 1.2 g ammonium molybdate ((NH4)6Mo7O24·4H2O in 9.8 ml 12 N H2SO4) 
 Sol B: 10 g ferrous ammonium sulfate (Fe(NH4)2(SO4)2·6H2O in 70 ml H2O) 
 Add sol A to sol B while stirring 
 Bring to a final volume of 100 ml with H2O 
 Store at 4°C 
 
STEM 
 To 700 ml H2O add 
 100 ml 1 M TES 
 4.29 g Mg(CH3CO2)2·4H2O 
 85.5 g sucrose 
 0.0951 g EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic 
acid) 
 5 g EACA (6-aminocaproic acid) 
 Adjust pH to 6.5 with 6M NaOH 
 Bring to a final volume of 1000 ml with H2O 
 Freeze in plastic bottles at -20°C 
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TES 50 
 To 700 ml H2O add 
 50 ml 1 M TES 
 150 ml glycerol 
 5 g EACA (6-aminocaproic acid) 
 1 g PAB (4-aminobenzamidine dihydrochloride) 
 Adjust pH to 6.5 with 6M NaOH 
 Bring to a final volume of 1000 ml with H2O 
 Freeze in plastic bottles at -20°C 
 
TES 5 + PAB 
 To 700 ml H2O add 
 5 ml 1 M TES 
 150 ml glycerol 
 1 ml 0.5 M DTT (dithiothreitol) 
 5 g EACA (6-aminocaproic acid) 
 1 g PAB (4-aminobenzamidine dihydrochloride) 
 2.5 ml 0.2 M EDTA (ethylenediaminetetraacetic acid disodium salt dihydrate) 
 Adjust pH to 6.5 with 6M NaOH 
 Freeze in plastic bottles at -20°C 
 
AET (argenine ent thiamine) 
 To 60 ml H2O add 
 0.617 g 2,3 dihydroxy benzoic acid 
 16.86 g L-arginine HCl 
 1 ml 20 mM thiamine 
 Add just enough amount of 1M NaOH to dissolve everything 
 Make final volume to 100 ml with H2O 
 Filter sterilize 
 
TE (trace elements) 
 To 80 ml H2O 
 0.251 g zinc sulfate (ZnSO4.7H2O) 
 0.017 g manganese sulfate (MnSO4.H2O) 
 0.029 g boric acid (H3BO3) 
 0.012 g calcium sulfate (CaSO4.2H2O) 
 0.037 g calcium chloride (CaCl2.2H2O) 
 0.049 g ferric chloride (FeCl3.6H2O) 
 Make final volume to 100 ml with H2O. 
 Filter sterilize 
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ILV (isoleucine-valine) 
 To 95 ml H2O add 
 0.394 g isoleucine 
 0.352 g valine 
 Make final volume to 100 ml with H2O 
 Filter sterilize 
 
Potassium phosphate buffer (0.1 M) pH 7.2 (Green, 1933) 
 71.7 ml 1 M K2HPO4 
 28.3 ml 1 M KH2PO4 
 Dilute the 1M stock solution to 1000 ml with distilled H2O. pH may be calculated 
using the Henderson-Hasselbalch equation. 
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Appendix B 
Culture Media and Plates 
LB liquid medium 
 12.5 g of LB broth powder 
 Add H2O to bring to 500 ml 
 Autoclave for 30 minutes 
 Cool the media to ~50°C 
 Add 500 μl of 100 mg/ml Ampicillin 
 
Minimal glucose 
 Minimal media 
o To 400 ml H2O add 
o 5.225 g potassium phosphate dibasic (K2HPO4) 
o 2.40 g sodium phosphate monobasic (NaH2PO4) 
o 0.99 g ammonium sulfate ((NH4)2SO4) 
o Autoclave for 30 min, cool to room temperature 
 Additions 
o 10 ml uracil 
o 1 ml 27 % glucose (3 mM) 
o 5 ml isoleucin-valine (ILV) 
o 0.5 ml trace elements (TE) 
o 0.5 ml 1 M magnesium sulfate (MgSO4) 
o 0.5 ml argenine ent thimine (AET) 
o 0.5 ml 100 mg/ml ampicillin 
o 3.12 ml 4X LB 
 
LB-agar plate with ampicillin 
 12.5g of LB broth powder 
 7.5g of agar 
 Bring to a final volume of 500 mL with H2O 
 Autoclave for 30 minutes 
 Cool the media to ~50°C 
 Add 500 μl of 100 mg/ml ampicillin 
 Pour into sterile plates 
 
Succinate Broth 
 Prepare 500 ml minimal media 
 Additions 
o 10 ml uracil 
o 10 ml 17.7% succinate 
 To 300 ml H2O add 
 88.5 g succinic acid 
 50 g NaOH 
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 Adjust to pH 7.0, bring to 500 ml, and autoclave 
 This solution becomes hot when dissolving: stir in an ice bath. 
o 0.5 ml TE 
o 0.5 ml 1 M MgSO4 
o 0.5 ml AET 
o 5 ml 6% casamino acids (CAS) optional 
o 0.5 ml 100 mg/ml ampicillin 
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Appendix C 
Membrane Preparation and ATPase Assays 
Membrane preparation 
Starter Culture:  Make using aseptic technique.  Always perform limiting glucose and 
succinate growth curves before preparing membranes (Mbr).   
 
DAY 1:   
Prepare solutions.  Inoculate LB broth tubes with a single colony and grow O/N (16-20 
hrs) at 37°C and 250 RPM in water/air shaker. 
 
DAY 2:   
1.  Prepare duplicate starter culture flasks.   
a) Prepare minimal media (MM) in one large batch.  Dissolve and separate into 250 
mL flasks with 50 mL each.  Cap each flask with foam and aluminum foil.  
Autoclave on liquid cycle for 20-30 min.   
b) Once 50 mL MM has cooled, make the following additions: 
1. 50 μl TE  
2. 50 μl 1 M MgSO4   
3. 50 μl AET  
4. 50 μl ampicillin (100 mg/mL) or 100 μl ampicillin (50 mg/mL) 
5. 1 mL 27% glucose (30 mM) 
6. 1 mL 0.11% uracil 
7. 500 μl IlV 
8. 312 μl 4XLB (2.5% LB in final volume) 
2. Inoculate each 50 mL flask with 10-15 μl of LB amp broth which has been 
previously grown O/N (16-20 hrs) at 37°C, 250 RPM.  
3. Grow in 37°C water/air shaker at 250 RPM for 6-8 hours.   
4. Once the 50 mL flasks have grown for 6-8 hours, they will be used as the inoculums 
for the 1 L flasks.   
5. To the 1L MM flask, make the following additions: 
1. 1000μl TE  
2. 1000μl 1M MgSO4   
3. 1000μl AET  
4. 1000μl ampicillin (100 mg/mL) or 2000 μl ampicillin (50 mg/mL) 
5. 20 mL 27% glucose  
6. 20 mL 0.11% uracil 
7. 10 mL IlV  
8. 6240μl 4XLB 
6. Grow in 37°C water/air shaker at 250 RPM for 6-8 hours.  Read OD595 every hour 
until late log phase.  Sometimes longer than 8 hours is required for mutants.  
7. Go to harvesting cells. 
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Harvesting Cells:  All steps below should be on ice or at 2°C.  
1. Spin suspension with Super Speed RC5B centrifuge in a Sorvall GSA rotor at 9500 
RPM X 15 min in 250 mL polycarbonate bottles.   
2. Resuspend combined pellets in STEM at 2°C using clean paint brush (rinse with 
dH2O).   
3. Spin at 9500 RPM for 25 min.  Aim to combine pellets in same container throughout 
the next few steps.   
4. Weigh pellet by difference and resuspend pellet in 2 mL STEM/g wet cells.   
Freeze bottle with cells in -80°C overnight or proceed directly to next step.  Do not 
store longer than overnight.   
 
DAY 3: 
French Press and TES 50 Wash:   
1. Thaw cells on ice.  Add 15-20 mg of DNAse (Deoxyribonuclease I from bovine 
pancreas) to the thawed pellet.   
2. Slowly pass through chilled French press twice at 20K psi. 
3. Spin with ultra-centrifuge WX80 in 65 Ti rotor at 22K RPM for 20 min for DK8: for 
other strains spin at 18K RPM for 20 min.   
4. Discard pellet and spin supernatant at 60K RPM for 2 hr at 2°C.  Fill tubes with 
STEM. 
5. Resuspend pellets in TES 50 with paint brush.   
6. Spin at 60K RPM for 2hr at 2°C.   
7. Discard supernatant.  Freeze pellets (in tube) in -80°C or go to next step. 
 
TES 5 + PAB Wash:   
1. Thaw pellet on ice.   
2. Resuspend pellets in TES 5 + PAB.   
3. Spin with ultra-centrifuge WX80 in 65 Ti rotor at 60K RPM for 75-90 min.   
4. Repeat steps 2 and 3. 
5. Freeze pellet in -80°C, go to F1 prep (not shown), or go to membrane resuspension. 
 
Membrane Resuspension:   
1. Add 500-800 μl 50 mM Tris sulfate pH 8 (T8) to centrifuge tube and resuspend using 
small paint brush to avoid frothing. 
2. Thoroughly resuspend pellet. Transfer to microfuge tube.   
3. Final volume of membrane should contain 2.5 mM MgSO4.   
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4. Store in -20°C for immediate use or in -80°C for longer storage. 
5. Find protein concentration using the Bradford method and bovine serum albumin 
(BSA) as a standard.    
 
ATPase assays 
 
1.  According to growth assays, amount and time of reaction will vary.   
     In general, the reaction will proceed as follows: 
 
50mM T8 + Mbr + ATPcocktail + 10% SDS + T&S (2-5 min) 
  
2.  The blank reaction will proceed as follows: 
 
50mM T8 + Mbr + 10% SDS + ATPcocktail + T&S (2-5 min) 
 
3.  Read OD700. 
4.  For a total reaction volume of 100 μl with a membrane that is 10 μg protein/μl, add 2 
μl for 20 μg protein, and 98 μl of T8 for a final volume of 100 μl.  Where other 
solutions are added, the volume of T8 is adjusted to maintain a reaction volume of 
100 μl. 
5.  The ratio of ATPcocktail, SDS, and T&S should be 1:1:1. 
6.  Vortex after addition of each solution.   
7.  Specific Activity = (Sample OD – Blank OD) / [Amount (mg) X Time (min)] 
 
NOTES:  
 Add Mbr to start reaction. 
 Assays should be performed in duplicate. 
 Membranes should be kept on ice. 
 All reactions take place at room temperature. 
 To reduce error, make a cocktail of Mbr and T8 and pipette 10 µl per tube. 
 After ATPcocktail is thawed in cold water, move it to ice. 
 Blanks used for initial, midpoint, and final concentrations unless noted otherwise. 
 Volumes and stock solution molarities may have been different than shown in 
tables. 
 Number of tubes needed may vary. 
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Inhibition by NBD-Cl:  Light sensitive: complete reaction in dark. 
 Additions of NBD-Cl may not yield an exact μM concentration.   
 Blanks for tubes 0, 7, 13. 
 NBD-Cl stock and dilutions made in DMSO. 
 
NBD-Cl Stock Tube # NBD-Cl (μl) [NBD-Cl] (μM) T8 (μl) Mbr (μl) 
 0 0 0 89 10 
250 μM 
1 2 5 87 10 
2 4 10 85 10 
3 6 15 83 10 
4 8 20 81 10 
5 10 25 79 10 
500 μM 
6 8 40 81 10 
7 10 50 79 10 
2500 μM 
8 3 75 86 10 
9 4 100 85 10 
10 6 150 83 10 
11 8 200 81 10 
12 10 250 79 10 
13 12 300 77 10 
14 16 400 73 10 
 
Inhibition by NaN3: 
 Incubate for 30 min with NaN3 
 
NaN3 Stock Tube # NaN3 (μl) NaN3 (µM) T8 (μl) Mbr (μl) 
2.5mM 
0 0 0 89 10 
1 1 25 88 10 
2 2 50 87 10 
3 4 100 85 10 
4 6 150 83 10 
5 8 200 81 10 
6 10 250 79 10 
7 12 300 77 10 
8 14 350 75 10 
9 16 400 73 10 
10 18 450 71 10 
11 20 500 69 10 
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Inhibition with an Extra Pulse of NBD-Cl:   
 EXAMPLE OF CALCULATIONS: 
o 0.00015M(100 μl) = X μl (0.00052M [stock]) 
 2.885 μl stock NBD-Cl in each tube with reaction volume of 100 
μl for 150 μM NBD-Cl. 
o 0.0002M (100 μl) = X μl (0.0052M [stock]) 
 3.846 μl stock NBD-Cl in each tube with reaction volume of 100 
μl for 200 μM NBD-Cl. 
 Treatment tube: 
50 mM T8 + Mbr + 150 μM NBD-Cl (inc 1h) + 150 μM NBD-Cl (inc 1h) + 
ATPcocktail + 10% SDS + T&S (2-5 min) 
 Blank tube: 
50 mM T8 + Mbr + 150 μM NBD-Cl (inc 1h) + 150 μM NBD-Cl (inc 1h) + 10% 
SDS + ATPcocktail + T&S (2-5 min) 
 One blank for each tube. 
 
Tube # 150 μM NBD-Cl T8 (μl) Mbr (μl) 150 μM NBD-Cl 
1 2.89 μl 5200 μM stock  86.11 10 NONE 
2 2.89 μl 5200 μM stock 86.11 10 3.85 μl 5200 μM stock 
DTT Reversibility of NBD-Cl Inhibition:  
Tube Number 
1. 50 mM T8 + Mbr + ATPcocktail + 10% SDS + T&S (2-5 min) 
 
2. 50 mM T8 + Mbr + 150 μM NBD-Cl (incubate 1h) + ATPcocktail + 10% SDS + 
T&S (2-5 min) 
 
3. 50 mM T8 + Mbr + 150 μM NBD-Cl (incubate 1h) + 4 mM DTT (inc 1h) + 
ATPcocktail + 10% SDS + T&S (2-5 min) 
 
4. 50 mM T8 + Mbr + 4 mM DTT (incubate 1h) + ATPcocktail + 10% SDS + T&S 
(2-5 min) 
 
 DTT stock kept on ice. 
 NBD-Cl reaction in dark. 
 Blank for each tube. 
  
Tube # 150 μM NBD-Cl T8 (μl) Mbr (μl) 4 mM DTT 
1 NONE 86.11 10 NONE 
2 2.89 μl 5200 μM stock 86.11 10 0.8 μl of 0.5 M stock 
3 NONE 86.11 10 0.8 μl of 0.5 M stock 
4 2.89 μl 5200 μM stock 86.11 10 NONE 
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MgADP Protection from NBD-Cl Inhibition: 
 Pre-incubate Mbr with MgADP at varying concentrations: 0-12mM (15 mM 
maximum). 
 Mg and ADP concentrations in a ratio of 1:1 
o MgSO4 stock 0.05M 
o NaADP stock 0.05M 
 Add 150 μM NBD-Cl in each tube except 0 tubes. 
 Blanks for tube 0, 11, and 16. 
 
Tube # Mg (μl) ADP (μl) [MgADP] (μM) T8 (μl) Mbr (μl) 150 μM NBD-Cl 
0 0 0 0 89 10 0 
1 1 1 0.5 87 10 
2.88 μl of 5.2 
mM stock 
2 1.5 1.5 0.75 86 10 
3 2 2 1 85 10 
4 3 3 1.5 83 10 
5 4 4 2 81 10 
6 5 5 2.5 79 10 
7 6 6 3 77 10 
8 7 7 3.5 75 10 
9 8 8 4 73 10 
10 9 9 4.5 71 10 
11 10 10 5 69 10 
12 11 11 5.5 67 10 
13 12 12 6 65 10 
14 14 14 8 61 10 
15 16 16 10 57 10 
16 18 18 12 53 10 
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MgPi Protection from NBD-Cl inhibition: 
1. Add T8. 
2. Add Pi + Mg. 
3. Add Mbr. 
4. Inc 1h at room temperature. 
5. To all, except tube #0, add 2 μl 
NBD-Cl. 
6. At 5 min, 10 min, 15 min…add 
ATPcocktail. 
7. Stop reaction at appropriate time. 
8. Read one set at a time. 
 
 
SET 1 
Tube # T8 (μl) Pi (25 mM) Mg (25 mM) Mbr (μl) NBD-Cl (2.5 mM) 
0 40 0 0 10 0 
1 38 0 0 10 2 
2 38 0 0 10 2 
3 38 0 0 10 2 
4 38 0 0 10 2 
5 38 0 0 10 2 
6 38 0 0 10 2 
SET 2 
Tube # T8 (μl) Pi (25 mM) Mg (25 mM) Mbr (μl) NBD-Cl (2.5 mM) 
0 40 0 0 10 0 
1 28 5 5 10 2 
2 28 5 5 10 2 
3 28 5 5 10 2 
4 28 5 5 10 2 
5 28 5 5 10 2 
6 28 5 5 10 2 
SET 3 
Tube # T8 (μl) Pi (25 mM) Mg (25 mM) Mbr (μl) NBD-Cl (2.5 mM) 
0 40 0 0 10 0 
1 28 5 5 10 2 
2 28 5 5 10 2 
3 28 5 5 10 2 
4 28 5 5 10 2 
5 28 5 5 10 2 
6 28 5 5 10 2 
SET 4 
Tube # T8 (μl) Pi (25 mM) Mg (25 mM) Mbr (μl) NBD-Cl (2.5 mM) 
0 40 0 0 10 0 
1 28 5 5 10 2 
2 28 5 5 10 2 
3 28 5 5 10 2 
4 28 5 5 10 2 
5 28 5 5 10 2 
6 28 5 5 10 2 
Tube # 
Assay at X 
min 
 0 5 
1 10 
2 15 
3 20 
4 30 
5 30 
6 40 
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Inhibition by DCCD:  
 One 16 h incubation and one 1 h incubation should be performed.  
 DCCD stock and dilutions should be made in DMSO. 
 
DCCD Stock Tube # DCCD (μl) [DCCD] (μM) T8 (μl) Mbr (μl) 
250 μM 
0 0 0 89 10 
1 2 5 87 10 
2 4 10 85 10 
3 8 20 81 10 
500 μM 
4 6 30 83 10 
5 8 40 81 10 
6 10 50 79 10 
2500 μM 
7 3 75 86 10 
8 4 100 85 10 
9 6 150 83 10 
10 8 200 81 10 
11 10 250 79 10 
5000 μM 
12 6 300 83 10 
13 8 400 81 10 
14 10 500 79 10 
 
101 
 
Inhibition by AlFx: 
 First a cocktail needs to be made: 
o 2.5m M MgSO4 (make 1 M stock and store at RT) 
o 10m M NaF (make 1 M stock and store at RT) 
o 1m M NaADP (make 0.5 M stock and store at -20°C) 
o Mbr (add enough so that there is 20 μg/tube) 
o Make final volume with T8 
o Mix by inverting tube 
 Here is an example for 2.5 ml of cocktail 
 6.5 μl 1 M MgSO4  2.6 mM 
 30 μl 1 M NaF  12 mM 
 6 μl 0.449 M NaADP  1 mM 
 X μl Mbr to get 20-30 μg each tube (25 tubes x 20 μg each500 
μg) 
 Vf with T8 
 For 10ml 
 26 μl 1 M MgSO4  2.6 mM 
 120 μl 1 M NaF  12 mM 
 24 μl 0.449 M NaADP  1 mM 
 i.e. 100 μl Mbr to get 20-30 μg each tube 
 Vf with T89730 μl 
 Each tube will have a final volume of 110 μl 
 
AlFx Stock Tube # AlFx (μl) [AlFx] (μM) T8 (μl) Cocktail (μl) 
  0 0 0 10 100 
2.5 mM 
1 1 0.0227 9 100 
2 2 0.0455 8 100 
3 3 0.0682 7 100 
4 4 0.09091 6 100 
5 5 0.11364 5 100 
6 6 0.1364 4 100 
7 7 0.1591 3 100 
8 8 0.1818 2 100 
25 mM 
9 1 0.2273 9 100 
10 1.5 0.34091 8.5 100 
11 2 0.45455 8 100 
12 2.5 0.5682 7.5 100 
13 3 0.68182 7 100 
14 3.5 0.79545 6.5 100 
15 4 0.90911 6 100 
16 5 1.1364 5 100 
17 6 1.36364 4 100 
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Inhibition by ScFx: 
 Follow same protocol as for AlFx 
 
ScFx Stock Tube # ScFx (μl) [ScFx] (μM) T8 (μl) Cocktail (μl) 
  0 0 0 10 100 
1.03 mM 
1 2 0.019 8 100 
2 3 0.028 7 100 
3 4 0.037 6 100 
4 5 0.047 5 100 
5 6 0.056 4 100 
6 7 0.065 3 100 
7 8 0.075 2 100 
8 1 0.094 9 100 
10.3 mM 
9 1.5 0.14 8.5 100 
10 2.5 0.234 7.5 100 
11 3.5 0.33 6.5 100 
12 5 0.468 5 100 
13 5.5 0.515 4.5 100 
14 6 0.66 4 100 
15 8.5 0.796 1.5 100 
16 10 0.936 0 100 
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Appendix D 
Raw Data 
Growth Yield in Limiting Glucose for Multiple VISIT Mutants 
 
Plasmid Mutation % Avg. OD 
WT N/A 100 
pSN6 βY331W 94 
pUC118 UNC- 37 
pLEB1 αV345R/βY331W 46 
pLEB2 αI346R/βY331W 74 
pLEB3 αS347R/βY331W 46 
pLEB4 αI348R/βY331W 64 
pLEB5 αT349R/βY331W 49 
pLEB6 αV345D/βY331W 75 
pLEB7 αI346D/βY331W 76 
pLEB8 αS347D/βY331W 46 
pLEB9 αI348D/βY331W 77 
pLEB10 αT349D/βY331W 61 
pLEB11 αI346A/βY331W 99 
pLEB12 αI348A/βY331W 92 
pLEB13 αT349A/βY331W 54 
pLEB14 βR182A/βY331W 46 
pLEB15 αT349R/βR182A/βY331W 48 
Average optical density calculated from at least two replicates.  
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Biochemical Assay Data 
In all tables below, data averaged from duplicate assay tubes. 
Strain WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
Amount of Mbr (mg) 0.02 0.08 0.02 0.02 0.01 0.01
Icubation time with ATP (min) 5 90 60 10 90 90
0 0.59 0.59 0.42 0.37 0.30 0.34
5 0.46 0.52 0.39 0.31 0.31 0.33
10 0.48 0.53 0.38 0.27 0.31 0.34
15 0.41 0.56 0.34 0.27 0.31 0.33
20 0.36 0.42 0.31 0.25 0.29 0.33
25 0.30 0.38 0.30 0.21 0.29 0.32
40 0.21 0.30 0.24 0.18 0.29 0.33
50 0.18 0.30 0.22 0.16 0.27 0.34
75 0.11 0.27 0.19 0.13 0.24 0.29
100 0.09 0.22 0.17 0.11 0.23 0.27
150 0.08 0.20 0.15 0.11 0.23 0.27
200 0.07 0.26 0.15 0.11 0.25 0.27
250 0.08 0.21 0.16 0.13 0.24 0.28
300 0.07 0.21 0.14 0.11 0.24 0.31
400 0.07 0.21 0.15 0.11 0.24 0.27
Average Blank OD700 0.06 0.13 0.11 0.13 0.16 0.18
Amount of Mbr (mg) 0.08 0.02 0.02 0.08 0.08
Icubation time with ATP (min) 90 60 10 90 90
0 0.65 0.43 0.37 0.33 0.38
5 0.65 0.40 0.30 0.34 0.38
10 0.61 0.35 0.27 0.33 0.41
15 0.56 0.35 0.23 0.33 0.33
20 0.48 0.31 0.21 0.30 0.36
25 0.42 0.26 0.19 0.32 0.39
40 0.40 0.23 0.15 0.32 0.33
50 0.33 0.22 0.15 0.28 0.37
75 0.28 0.17 0.12 0.27 0.29
100 0.23 0.16 0.12 0.24 0.29
150 0.22 0.15 0.11 0.26 0.29
200 0.24 0.15 0.12 0.26 0.27
250 0.25 0.15 0.12 0.25 0.26
300 0.22 0.16 0.12 0.24 0.29
400 0.22 0.15 0.10 0.25 0.26
Average Blank OD700 0.14 0.11 0.11 0.15 0.15
Inhibiton of ATPsynthase by NBD-Cl (1)
Inhibiton of ATPsynthase by NBD-Cl (2)
Average OD700 at varying [NBD-Cl] (μM)
Average OD700 at varying [NBD-Cl] (μM)
 
105 
 
Strain WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
Amount of Mbr (mg) 0.1 0.1
Icubation time with ATP (min) 120 120
0.31 0.38
0.29 0.36
0.30 0.39
0.29 0.39
0.27 0.38
0.28 0.31
0.27 0.33
0.25 0.35
0.23 0.30
0.22 0.28
0.21 0.27
0.22 0.27
0.22 0.27
0.22 0.28
0.21 0.30
Average Blank OD700 0.15 0.16
Amount of Mbr (mg) 0.1 0.1
Icubation time with ATP (min) 120 120
0.31 0.37
0.30 0.37
0.27 0.36
0.31 0.36
0.30 0.36
0.29 0.35
0.27 0.33
0.25 0.33
0.22 0.30
0.22 0.29
0.21 0.27
0.24 0.27
0.22 0.26
0.21 0.26
0.21 0.26
Average Blank OD700 0.15 0.15
Inhibiton of ATPsynthase by NBD-Cl (4)
Average OD700 at varying [NBD-Cl] (μM)
Inhibiton of ATPsynthase by NBD-Cl (3)
Average OD700 at varying [NBD-Cl] (μM)
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WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
0.02 0.08 0.02 0.02 0.1 0.1
7 90 60 20 90 90
Tube
1 Mbr only 1.01 0.65 0.81 0.92 0.28 0.33
2 NBD-Cl+DTT 0.61 0.46 0.55 0.57 0.21 0.22
3 DTT 0.94 0.70 0.87 0.96 0.31 0.38
4 NBD-Cl 0.08 0.21 0.09 0.04 0.20 0.30
1 Blank 1 0.08 0.11 0.05 0.07 0.15 0.17
2 Blank 2 0.06 0.11 0.04 0.10 0.09 0.10
3 Blank 3 0.06 0.11 0.05 0.07 0.15 0.17
4 Blank 4 0.07 0.11 0.04 0.07 0.16 0.17
0.02 0.08 0.02 0.02 0.1 0.1
7 90 60 20 90 90
Tube
1 Mbr only 1.00 0.68 0.74 1.03 0.28 0.35
2 NBD-Cl+DTT 0.62 0.58 0.43 0.56 0.18 0.25
3 DTT 0.79 0.68 1.09 0.91 0.32 0.38
4 NBD-Cl 0.09 0.20 0.11 0.10 0.20 0.27
1 Blank 1 0.07 0.11 0.05 0.11 0.14 0.16
2 Blank 2 0.06 0.11 0.05 0.12 0.08 0.11
3 Blank 3 0.06 0.11 0.05 0.11 0.14 0.24
4 Blank 4 0.07 0.11 0.05 0.12 0.14 0.18
Strain
Amount of Mbr (mg)
Icubation time with ATP (min)
Average OD700 
Average OD700 
DTT Reversibility of ATPsynthase Inhibiton by NBD-Cl  (1)
DTT Reversibility of ATPsynthase Inhibiton by NBD-Cl  (2)
Amount of Mbr (mg)
Icubation time with ATP (min)
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WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
0.08 0.02 0.02 0.02 0.1
90 60 60 20 120
Tube
1 Mbr only 0.88 0.58 0.73 1.33 0.23
2 NBD-Cl+DTT 0.64 0.52 0.61 0.97 0.27
3 DTT 0.92 0.64 0.73 0.93 0.26
4 NBD-Cl 0.12 0.17 0.14 0.09 0.16
1 Blank 1 0.10 0.09 0.08 0.05 0.11
2 Blank 2 0.10 0.09 0.08 0.06 0.15
3 Blank 3 0.09 0.09 0.08 0.06 0.15
4 Blank 4 0.10 0.09 0.08 0.06 0.14
0.08 0.02 0.02 0.02 0.1
90 60 60 20 120
Tube
1 Mbr only 0.86 0.62 0.74 0.94 0.30
2 NBD-Cl+DTT 0.60 0.50 0.55 0.67 0.40
3 DTT 0.82 0.59 0.74 0.55 0.28
4 NBD-Cl 0.11 0.18 0.13 0.08 0.23
1 Blank 1 0.09 0.09 0.08 0.04 0.15
2 Blank 2 0.08 0.09 0.08 0.06 0.17
3 Blank 3 0.08 0.10 0.08 0.07 0.16
4 Blank 4 0.09 0.12 0.08 0.07 0.17
Strain
Icubation time with ATP (min)
Average OD700 
Average OD700 
DTT Reversibility of ATPsynthase Inhibiton by NBD-Cl  (4)
DTT Reversibility of ATPsynthase Inhibiton by NBD-Cl  (3)
Amount of Mbr (mg)
Amount of Mbr (mg)
Icubation time with ATP (min)
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WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
0.02 0.08 0.02 0.02 0.1 0.1
6 90 60 15 90 90
Tube
B1 Blank 1 0.04 0.05 0.03 0.04 0.10 0.10
B2 Blank 2 0.04 0.06 0.04 0.04 0.10 0.10
B3 Blank 3 0.04 0.05 0.03 0.04 0.10 0.10
1 Mbr only 0.62 0.56 0.36 0.55 0.23 0.26
2 NBD-Cl (150 μM) 0.07 0.16 0.06 0.05 0.17 0.21
3 NBD-Cl (150 μM + 150 μM) 0.05 0.13 0.05 0.05 0.15 0.20
0.02 0.08 0.02 0.02 0.1 0.1
6 90 60 15 90 90
Tube
B1 Blank 1 0.056 0.052 0.034 0.044 0.104 0.104
B2 Blank 2 0.056 0.059 0.033 0.040 0.100 0.110
B3 Blank 3 0.056 0.055 0.034 0.038 0.098 0.106
1 Mbr only 0.729 0.550 0.386 0.497 0.229 0.277
2 NBD-Cl (150 μM) 0.078 0.156 0.067 0.048 0.163 0.220
3 NBD-Cl (150 μM + 150 μM) 0.062 0.124 0.050 0.045 0.158 0.195
Average OD700 
Average OD700 
Strain
Amount of Mbr (mg)
Icubation time with ATP (min)
Inhibiton of ATPsynthase by an Extra Pulse of NBD-Cl (1)
Inhibiton of ATPsynthase by an Extra Pulse of NBD-Cl (2)
Amount of Mbr (mg)
Icubation time with ATP (min)
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Strain WT
pLEB5 
(αT349R/
βY331W)
pLEB10 
(αT349R/
βY331W)
pLEB13 
(αT349R/
βY331W)
pLEB14 
(αT349R/
βY331W)
pLEB15 
(αT349R/
βY331W)
Amount of Mbr (mg) 0.02 0.08 0.02 0.02 0.01 0.01
Icubation time with ATP (min) 5 90 60 15 90 90
0 0.12 0.18 0.12 0.09 0.18 0.21
0.5 0.48 0.23 0.14 0.10 0.18 0.25
0.75 0.44 0.24 0.13 0.11 0.18 0.27
1 0.43 0.27 0.13 0.11 0.20 0.31
1.5 0.46 0.26 0.14 0.11 0.20 0.30
2 0.46 0.27 0.15 0.13 0.21 0.30
2.5 0.50 0.27 0.14 0.13 0.21 0.31
3 0.50 0.29 0.16 0.14 0.22 0.31
3.5 0.50 0.30 0.16 0.15 0.21 0.33
4 0.49 0.29 0.17 0.16 0.22 0.34
4.5 0.51 0.31 0.23 0.18 0.22 0.35
5 0.51 0.32 0.19 0.21 0.23 0.34
5.5 0.57 0.34 0.21 0.24 0.23 0.34
6 0.59 0.30 0.22 0.21 0.23 0.36
8 0.44 0.33 0.24 0.26 0.24 0.35
10 0.69 0.37 0.26 0.31 0.24 0.37
12 0.83 0.40 0.30 0.36 0.26 0.36
Blank 0 0.12 0.08 0.08 0.08 0.11 0.11
0 0.12 0.19 0.12 0.09 0.17 0.22
0.5 0.42 0.22 0.11 0.10 0.19 0.27
0.75 0.38 0.23 0.11 0.13 0.20 0.26
1 0.42 0.24 0.11 0.13 0.23 0.28
1.5 0.43 0.24 0.13 0.12 0.25 0.29
2 0.45 0.27 0.12 0.13 0.21 0.31
2.5 0.47 0.29 0.13 0.12 0.24 0.30
3 0.50 0.27 0.14 0.13 0.23 0.31
3.5 0.52 0.30 0.15 0.14 0.23 0.31
4 0.53 0.31 0.17 0.16 0.23 0.33
4.5 0.56 0.32 0.17 0.17 0.26 0.32
5 0.56 0.34 0.19 0.20 0.24 0.34
5.5 0.58 0.34 0.19 0.21 0.26 0.34
6 0.63 0.35 0.20 0.22 0.27 0.35
8 0.68 0.37 0.20 0.26 0.27 0.33
10 0.76 0.38 0.25 0.30 0.27 0.34
12 0.82 0.40 0.28 0.36 0.27 0.37
Blank 0 0.12 0.09 0.08 0.08 0.10 0.11
Protection from NBD-CL Inhibiton of ATPsynthase by MgADP (1)
Average OD700 at varying [MgADP] mM
Average OD700 at varying [MgADP] mM
Protection from NBD-CL Inhibiton of ATPsynthase by MgADP (2)
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WT WT Blank
pLEB5 
(αT349R/
βY331W)
pLEB5 
Blank
pLEB10 
(αT349R/
βY331W)
pLEB10 
Blank
Time (min)
0 0.86 0.08 0.55 0.07 0.28 0.04
5 0.54 0.11 0.29 0.08 0.25 0.04
10 0.37 0.09 0.22 0.07 0.18 0.04
15 0.26 0.09 0.22 0.07 0.16 0.04
20 0.17 0.08 0.19 0.07 0.13 0.04
25 0.15 0.09 0.17 0.08 0.10 0.04
30 0.13 0.08 0.15 0.07 0.11 0.04
35 0.10 0.08 0.15 0.07 0.09 0.04
40 0.09 0.07 0.17 0.07 0.09 0.04
60 0.08 0.06 0.18 0.08 0.07 0.04
Time (min)
0 0.77 0.08 0.55 0.08 0.50 0.05
5 0.50 0.08 0.58 0.37 0.55 0.31
10 0.91 0.38 0.57 0.37 0.52 0.31
15 0.95 0.38 0.55 0.38 0.49 0.31
20 0.76 0.36 0.54 0.37 0.49 0.31
25 0.74 0.37 0.53 0.36 0.49 0.32
30 0.73 0.36 0.55 0.34 0.45 0.32
35 0.70 0.36 0.52 0.36 0.48 0.32
40 0.62 0.36 0.51 0.36 0.42 0.32
60 0.55 0.39 0.48 0.35 0.39 0.32
Time (min)
0 0.77 0.07 0.57 0.08 0.50 0.05
5 0.55 0.09 0.87 0.64 0.79 0.57
10 1.22 0.64 0.87 0.64 0.76 0.57
15 1.16 0.64 0.85 0.64 0.74 0.57
20 1.14 0.64 0.84 0.68 0.74 0.57
25 1.03 0.63 0.85 0.64 0.71 0.57
30 1.05 0.62 0.84 0.64 0.72 0.57
35 1.05 0.61 0.82 0.66 0.69 0.57
40 0.96 0.61 0.82 0.65 0.68 0.57
60 0.83 0.63 0.78 0.64 0.63 0.54
Time (min)
0 0.09 0.79 0.57 0.08 0.49 0.05
5 0.10 0.56 1.36 1.16 1.24 1.06
10 1.14 1.59 1.40 1.17 1.20 1.05
15 1.15 1.55 1.34 1.17 1.21 1.06
20 1.27 1.59 1.37 1.21 1.19 1.07
25 1.18 1.49 1.37 1.22 1.18 1.06
30 1.15 1.53 1.35 1.18 1.18 1.09
35 1.16 1.50 1.34 1.17 1.18 1.07
40 1.13 1.49 1.32 1.18 1.17 1.08
60 1.14 1.33 1.32 1.16 1.12 1.06
Strain
MgPi protection from inhibition by NBD-Cl of ATPsynthase (1)
Amount of Mbr (mg)
Icubation time with ATP (min)
0.02
60
Set 3      
(5 mM 
MgPi)
Average OD700 
90
0.08 0.02
60
Set 4      
(10 mM 
MgPi)
Average OD700 
Average OD700 
Set 2      
(2.5 mM 
MgPi)
Average OD700 
Set 1      
(0 mM 
MgPi)
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pLEB13 pLEB13 pLEB14 pLEB14 pLEB15 pLEB15 
Time (min)
0 0.37 0.05 0.22 0.06 0.25 0.06
5 0.37 0.05 0.16 0.07 0.22 0.07
10 0.23 0.05 0.15 0.06 0.20 0.07
15 0.13 0.05 0.15 0.06 0.19 0.07
20 0.12 0.05 0.13 0.07 0.18 0.08
25 0.11 0.05 0.13 0.06 0.20 0.07
30 0.08 0.05 0.14 0.06 0.18 0.07
35 0.07 0.05 0.13 0.06 0.18 0.07
40 0.07 0.05 0.14 0.06 0.18 0.07
60 0.06 0.05 0.13 0.06 0.18 0.07
Time (min)
0 0.38 0.05 0.20 0.08 0.25 0.09
5 0.80 0.33 0.45 0.34 0.46 0.33
10 0.74 0.33 0.43 0.36 0.47 0.33
15 0.66 0.33 0.42 0.36 0.47 0.33
20 0.66 0.33 0.43 0.36 0.46 0.33
25 0.60 0.33 0.46 0.35 0.47 0.33
30 0.62 0.34 0.43 0.36 0.45 0.33
35 0.57 0.33 0.42 0.37 0.46 0.34
40 0.56 0.34 0.43 0.35 0.46 0.34
60 0.53 0.34 0.43 0.35 0.43 0.33
Time (min)
0 0.36 0.05 0.19 0.07 0.26 0.07
5 1.02 0.61 0.69 0.61 0.76 0.61
10 0.98 0.60 0.69 0.62 0.77 0.62
15 0.94 0.61 0.69 0.64 0.76 0.64
20 0.89 0.60 0.70 0.64 0.75 0.62
25 0.90 0.61 0.72 0.62 0.76 0.62
30 0.87 0.59 0.70 0.62 0.74 0.63
35 0.80 0.60 0.70 0.61 0.74 0.61
40 0.83 0.61 0.70 0.62 0.76 0.63
60 0.77 0.59 0.69 0.62 0.74 0.62
Time (min)
0 0.42 0.05 0.20 0.08 0.27 0.07
5 1.45 1.11 1.20 1.11 1.25 1.12
10 1.42 1.11 1.19 1.13 1.28 1.11
15 1.40 1.11 1.19 1.14 1.27 1.13
20 1.34 1.12 1.23 1.12 1.25 1.12
25 1.38 1.11 1.19 1.13 1.24 1.15
30 1.34 1.12 1.21 1.13 1.26 1.13
35 1.33 1.10 1.20 1.12 1.28 1.14
40 1.34 1.13 1.21 1.13 1.24 1.14
60 1.30 1.13 1.19 1.12 1.23 1.14
MgPi protection from inhibition by NBD-Cl of ATPsynthase (1)
Strain
0.02 0.1 0.1
Icubation time with ATP (min) 20 120 90
Amount of Mbr (mg)
Set 3      
(5 mM 
MgPi)
Set 4      
(10 mM 
MgPi)
Set 1      
(0 mM 
MgPi)
Set 2      
(2.5 mM 
MgPi)
Average OD700 
Average OD700 
Average OD700 
Average OD700 
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WT WT Blank
pLEB13 
(αT349R/
βY331W)
pLEB13 
Blank
Time (min)
0 0.95 0.08 0.55 0.04
5 0.50 0.08 0.26 0.04
10 0.36 0.07 0.19 0.05
15 0.25 0.07 0.13 0.07
20 0.18 0.07 0.16 0.05
25 0.15 0.07 0.13 0.04
30 0.11 0.07 0.08 0.04
35 0.10 0.07 0.06 0.05
40 0.16 0.06 0.06 0.07
60 0.08 0.05 0.05 0.05
Time (min)
0 0.91 0.09 0.53 0.06
5 0.99 0.35 0.61 0.31
10 0.96 0.35 0.63 0.31
15 0.88 0.34 0.62 0.34
20 0.79 0.35 0.56 0.31
25 0.82 0.34 0.50 0.34
30 0.78 0.34 0.52 0.31
35 0.78 0.34 0.50 0.32
40 0.72 0.35 0.54 0.32
60 0.56 0.33 0.53 0.32
Time (min)
0 0.92 0.09 0.52 0.05
5 1.17 0.60 0.87 0.59
10 1.17 0.60 0.86 0.56
15 1.09 0.60 0.83 0.57
20 1.10 0.61 0.79 0.57
25 1.10 0.60 0.78 0.56
30 1.02 0.60 0.78 0.57
35 1.01 0.61 0.75 0.58
40 0.96 0.61 0.75 0.58
60 0.84 0.59 0.70 0.57
Time (min)
0 0.91 0.11 0.56 0.07
5 1.56 1.12 1.33 1.04
10 1.54 1.13 1.28 1.05
15 1.51 1.12 1.30 1.04
20 1.53 1.12 1.28 1.08
25 1.50 1.12 1.26 1.07
30 1.46 1.11 1.26 1.08
35 1.51 1.11 1.29 1.06
40 1.43 1.11 1.22 1.07
60 1.36 1.12 1.23 1.09
Strain
MgPi protection from inhibition by NBD-Cl of ATPsynthase (2)
Amount of Mbr (mg)
Icubation time with ATP (min)
Set 3      
(5 mM 
MgPi)
Average OD700 
Set 4      
(10 mM 
MgPi)
Average OD700 
0.08 0.02
20
Set 1      
(0 mM 
MgPi)
Average OD700 
Set 2      
(2.5 mM 
MgPi)
Average OD700 
90
 
113 
 
Appendix E 
Mutagenic Oligonucleotides 
 
Mutant Mutation Site Forward Primer Original codon→ Mutant 
codon 
Enzyme 
pLEB1 αV345R/βY331W GCGTTCGTTCCGACCAACCGAATTTC
CATTACCGATGGTCAG 
GTA→CGA 
ATC→ATT (SM) 
ApoI 
 
pLEB2 
 
αI346R/βY331W 
 
CGTTCGTTCCGACCAACGTAAGATCT
ATTACCGATGGTCAGATCTTC 
ATC→AGA TCC→TCT 
(SM) 
BglII 
 
pLEB3 
 
αS347R/βY331W 
 
TTCGTTCCGACCAACGTAATCCGGAT
TACCGATGGTCAGATCTTC 
TCC→CGG BspEI 
 
pLEB4 
 
αI348R/βY331W 
 
CGTTCGTTCCGACCAACGTAATCTCTA
GAACCGATGGTCAGATCTTCCTG 
ATT→AGA 
TCC→TCT (SM) 
XbaI 
 
pLEB5 
 
αT349R/βY331W 
 
GTTCCGACCAACGTAATCTCCATTCG
CGATGGTCAGATCT 
ACC→CGC NruI 
 
pLEB6 
 
αV345D/βY331W 
 
CGTTCGTTCCGACCAACGATATCTCC
ATTACCGATGGT 
GTA→GAT EcoRV 
 
pLEB7 
 
αI346D/βY331W 
 
CGTTCGTTCCGACCAACGTAGACTCC
ATTACCGATGG 
ATC→GAC AccI 
 
pLEB8 
 
αS347D/βY331W 
 
GTTCGTTCCGACCAACGTAATCGATA
TCACCGATGGTCAGATCTTCCTGG 
TCC→GAT 
ATT→ATC (SM) 
EcoRV 
 
pLEB9 
 
αI348D/βY331W 
 
CGTTCCGACCAACGTAATCTCAGATA
CCGATGGTCAGATCTTCCT 
ATT→GAT 
TCC→TCA (SM) 
DdeI 
 
pLEB10 
 
αT349D/βY331W 
 
GTTCCGACCAACGTAATCTCAATTGA
CGATGGTCAGATCTTCCTGG 
ACC→GAC 
TCC→TCA (SM) 
MfeI 
 
pLEB11 
 
αI346A/βY331W 
 
TTCTGCGTTCGTTCCGACCAACGTGGC
GTCCATAACCGATGGTCAG 
ATC→GCG 
GTA→GTG (SM) 
BsaHI 
 
pLEB12 
 
αI348A/βY331W 
 
GTTCGTTCCGACCAACGTAATCAGCG
CTACCGATGGTCAGATCTTCC 
ATT→GCT 
TCC→AGC (SM) 
HaeII 
 
pLEB13 
 
αT349A/βY331W GTTCCGACCAACGTAATCTATAGCCG
ATGGTCAGATCTTCCTG 
ACC→GCC 
TCC→TCT(SM) 
ATT→ATA (SM) 
SfcI 
 
pLEB14 
 
βR182A/βY331W 
 
GTTTGCGGGCGTAGGTGAAGCTACTC
GTGAGG 
CGT→GCT AluI 
 
pLEB15 
 
αT349R/βR182A/
βY331W 
Primer for pLEB14 used on pLEB5 plasmid. See pLEB14 and pLEB5 AluI 
NruI 
Name of the constructed plasmid is shown next to the mutation.  βY331W was used in all newly 
constructed plasmids.  Forward primers are shown with underlined nucleotides denoting the 
newly inserted mutation.  Silent mutations (SM) were introduced in some plasmids.  New 
restriction sites were inserted into all mutants; however, restriction analysis was not performed 
before or after sequencing. 
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